<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Itraconazole: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Itraconazole: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Itraconazole: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8586" href="/d/html/8586.html" rel="external">see "Itraconazole: Drug information"</a> and <a class="drug drug_patient" data-topicid="10780" href="/d/html/10780.html" rel="external">see "Itraconazole: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708958"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Congestive heart failure:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Itraconazole can cause or exacerbate congestive heart failure (CHF). When itraconazole was administered intravenously (IV) to dogs and healthy human volunteers, negative inotropic effects were seen. Do not administer itraconazole for the treatment of onychomycosis in patients with evidence of ventricular dysfunction, such as CHF or a history of CHF. If signs or symptoms of CHF occur during administration of itraconazole oral solution or capsule (65 mg [Tolsura]), reassess continued itraconazole use. If signs or symptoms of CHF occur during administration of itraconazole capsules (100 mg [Sporanox]), discontinue administration.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Drug interactions:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Coadministration of the following drugs is contraindicated with itraconazole: methadone, disopyramide, dofetilide, dronedarone, quinidine, isavuconazole, ergot alkaloids (eg, dihydroergotamine, ergometrine [ergonovine], ergotamine, methylergometrine [methylergonovine]), irinotecan, lurasidone, oral midazolam, pimozide, triazolam, felodipine, nisoldipine, ivabradine, ranolazine, eplerenone, cisapride, naloxegol, lomitapide, lovastatin, simvastatin, avanafil, ticagrelor, finerenone, and voclosporin. In addition, coadministration with colchicine, fesoterodine, and solifenacin is contraindicated in subjects with varying degrees of renal or hepatic impairment, and coadministration with eliglustat is contraindicated in subjects who are poor or intermediate metabolizers of CYP2D6 and in subjects taking strong or moderate CYP2D6 inhibitors. Coadministration with venetoclax is contraindicated in subjects with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) during the dose initiation and ramp-up phase of venetoclax. Coadministration with itraconazole can cause elevated plasma concentrations of these drugs and may increase or prolong both the pharmacologic effects and/or adverse reactions to these drugs. For example, increased plasma concentrations of some of these drugs can lead to QT prolongation and ventricular tachyarrhythmias including occurrences of torsades de pointes, a potentially fatal arrhythmia.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F185420"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Sporanox;</li>
<li>Sporanox Pulsepak [DSC];</li>
<li>Tolsura</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867288"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>JAMP Itraconazole;</li>
<li>MINT-Itraconazole;</li>
<li>ODAN Itraconazole;</li>
<li>Sporanox</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1048118"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antifungal Agent, Systemic</span></li></ul></div>
<div class="block dop drugH1Div" id="F185447"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information:</b> Oral formulations are not interchangeable. Generally, oral solution is the preferred formulation because of improved absorption (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-HHS.2022','lexi-content-ref-17968818']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-HHS.2022','lexi-content-ref-17968818'])">Ref</a></span>). Oral absorption varies between patients and as a result, monitoring of serum concentrations is suggested to ensure adequate and nontoxic levels are achieved (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1'])">Ref</a></span>). Capsules are available as two unique formulations (Sporanox [100 mg] and Tolsura [65 mg]) that are not interchangeable; where capsule is an applicable dosage form, dosing is presented for the 100 mg capsule (eg, Sporanox).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations:</b> Initial dosing recommendations presented; for most indications, dosing should be adjusted based on serum concentration monitoring.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosing:</b> Limited data available: Infants, Children, and Adolescents: Oral: 5 mg/kg/dose every 12 hours; maximum dose: 100 mg/dose; higher maximum doses may be appropriate for some indications; see indication-specific dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3fc50a14-5072-4f42-8e72-dfc3c96dfabf">Allergic bronchopulmonary aspergillosis in patients with cystic fibrosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Allergic bronchopulmonary aspergillosis in patients with cystic fibrosis: </b>Limited data available: <b>Note: </b>Typically recommended only in cases in which there is a poor response to corticosteroids, when corticosteroid toxicity or dependence is present, or for relapsed disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12975753']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12975753'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Oral: 5 mg/kg/dose every 12 to 24 hours for 3 to 6 months; maximum dose: 200 mg/dose; higher maximum doses may be appropriate based on serum concentrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-12975753']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-12975753'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="570d439f-e562-4821-bf02-f151021e7b4a">Blastomycosis, non-CNS infections</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Blastomycosis, non-CNS infections</b>: Limited data available: Infants, Children, and Adolescents: Oral solution: Oral: 5 mg/kg/dose every 12 hours; maximum dose: 200 mg/dose. Duration should be individualized based on disease severity, site of infection, and response to therapy; usual duration for mild to moderate disease is 6 to 12 months. For severe disease, initial therapy with amphotericin B is recommended for 1 to 2 weeks, followed by 6 to 12 months of itraconazole; ≥12 months of therapy is recommended for bone infections or in patients with immunocompromise (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30924967','lexi-content-ref-Bradley.1','lexi-content-ref-34364529','lexi-content-ref-18462107','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30924967','lexi-content-ref-Bradley.1','lexi-content-ref-34364529','lexi-content-ref-18462107','lexi-content-ref-AAP.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a474b86d-f618-403c-abc4-11a9a731c6ce">Candidiasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Candidiasis:</b>
<i>Patients with HIV:</i> Limited data available: <b>Note:</b> Typically reserved as an alternative agent or for fluconazole-refractory disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2022','lexi-content-ref-HHS.1','lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2022','lexi-content-ref-HHS.1','lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Oropharyngeal, treatment:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children: Oral solution: Oral: 2.5 mg/kg/dose every 12 hours for 7 to 14 days; maximum dose: 100 to 200 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12121932','lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12121932','lexi-content-ref-HHS.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents: Oral solution: Oral: 200 mg every 24 hours for 7 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12121932','lexi-content-ref-HHS.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12121932','lexi-content-ref-HHS.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Esophageal, treatment: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children: Oral solution: Oral: 2.5 mg/kg/dose every 12 hours for at least 21 days and at least 2 weeks following resolution of symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents: Oral solution: Oral: 200 mg every 24 hours for 14 to 21 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Vulvovaginal, uncomplicated:</i> Adolescents: Oral solution: Oral: 200 mg every 24 hours for 3 to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2022'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3b00d09b-403f-403b-bcd2-8c804ff3cf2d">Coccidioidomycosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Coccidioidomycosis:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Treatment:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Bone and/or joint infection</i>: <b>Note: </b>In some cases (eg, patients with severe disease or HIV), initial therapy should be with an amphotericin B product and then switched to an oral azole. Total duration of therapy depends on clinical response and immune status but is typically ≥1 year (often longer [eg, 3 years or lifetime]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-HHS.2022','lexi-content-ref-HHS.1','lexi-content-ref-27470238','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-HHS.2022','lexi-content-ref-HHS.1','lexi-content-ref-27470238','lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Infants, Children, and Adolescents: Oral: 5 mg/kg/dose every 12 hours. Maximum dose: 200 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-11074900','lexi-content-ref-HHS.2022','lexi-content-ref-HHS.1','lexi-content-ref-19884875']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-11074900','lexi-content-ref-HHS.2022','lexi-content-ref-HHS.1','lexi-content-ref-19884875'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Meningitis</i>: <b>Note: </b>Initiate therapy with an amphotericin B product until clinical improvement, then may switch to a triazole; fluconazole is preferred and itraconazole is considered an alternative option for adolescents; itraconazole is not included in guidelines for infants and children (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2022','lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2022','lexi-content-ref-HHS.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescents with HIV: Oral: 200 mg every 8 to 12 hours; therapy is lifelong due to high relapse rate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Pneumonia, focal (mild disease):</i> Patients with HIV: <b>Note: </b>Treatment duration depends on clinical response, typically ≥3 to 6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1','lexi-content-ref-27470238']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1','lexi-content-ref-27470238'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Infants, Children, and Adolescents: Oral: 2 to 5 mg/kg/dose every 8 hours for 3 days, followed by 2 to 5 mg/kg/dose every 12 hours; maximum dose: 200 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2022','lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2022','lexi-content-ref-HHS.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Secondary prophylaxis (chronic maintenance therapy) (alternative agent): Patients with HIV: <b>Note: </b>Recommended lifelong for patients with meningitis or disseminated disease; may be considered after milder disease if CD4 count &lt;250 cells/mm<sup>3</sup> or CD4 percentage &lt;15% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children: Oral: 2 to 5 mg/kg/dose twice daily; maximum dose: 200 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4e92319c-5908-4496-91af-dd3d80f81fad">Cryptococcal meningitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cryptococcal meningitis:</b> Patients with HIV: Limited data available: <b>Note:</b> Initial induction therapy with amphotericin B and flucytosine is recommended for at least 2 weeks, followed by consolidation therapy and secondary prophylaxis. Fluconazole is preferred for consolidation and secondary prophylaxis, as itraconazole is associated with inferior outcomes. Guidelines no longer recommend itraconazole in adolescent and adult patients; see guidelines for details (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2022','lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2022','lexi-content-ref-HHS.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Consolidation therapy:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children: Oral solution (preferred):</p>
<p style="text-indent:-2em;margin-left:8em;">Initial load: Oral: 2.5 to 5 mg/kg/dose 3 times daily for 3 days; maximum dose: 200 mg/dose.</p>
<p style="text-indent:-2em;margin-left:8em;">Maintenance dose: Oral: 5 to 10 mg/kg/day divided once or twice daily for a minimum of 8 weeks; maximum daily dose: 400 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Secondary prophylaxis (chronic maintenance therapy):</i> Infants and Children: Oral solution: Oral: 5 mg/kg/dose every 24 hours; maximum dose: 200 mg/dose. Discontinuation may be considered in patients ≥6 years who have been receiving antiretroviral therapy for ≥3 months and have CD4 cell count ≥100 cells/mm<sup>3</sup> and an undetectable viral load.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="da0b3cae-9a59-4ae8-9ed2-c6aad13abf2e">Histoplasmosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Histoplasmosis:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Pulmonary, acute primary disease: <b>Note: </b>For severe disease, therapy should be initiated with an amphotericin B product, and then switched to itraconazole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1','lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Patients with HIV:</i> Infants and Children: Oral solution (preferred): Oral: Initial: 2 to 5 mg/kg/dose every 8 hours for 3 days, followed by 2 to 5 mg/kg/dose every 12 hours for ≥12 months; maximum dose: 200 mg/dose. Treatment duration of 12 weeks may be adequate in children with functional cellular immunity (CD4 percentage &gt;20% or if age ≥6 years, CD4 cell count &gt;300 cells/mm<sup>3</sup>) if clinically improved and urine antigen concentrations decreased (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Patients without HIV:</i> Infants, Children, and Adolescents: Oral solution (preferred): Oral: 2.5 to 5 mg/kg/dose every 12 hours for 6 to 12 weeks; maximum dose: 200 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17806045']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17806045'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Disseminated disease: <b>Note: </b>For severe disease, therapy should be initiated with an amphotericin B product, and then transitioned to itraconazole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2022','lexi-content-ref-HHS.1','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2022','lexi-content-ref-HHS.1','lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Patients with HIV:</i> Infants, Children, and Adolescents: Oral solution (preferred): Oral: Initial: 2 to 5 mg/kg/dose every 8 hours for 3 days, followed by 2 to 5 mg/kg/dose every 12 hours for ≥12 months; maximum dose: 200 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2022','lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2022','lexi-content-ref-HHS.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Patients without HIV</i>: Infants, Children, and Adolescents: Oral solution (preferred): Oral: 2.5 to 5 mg/kg/dose every 12 hours for ≥3 to 12 months; duration depends on immune status, severity of illness, and clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17806045','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17806045','lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prophylaxis:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Primary: Adolescents with HIV: Oral: 200 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2022'])">Ref</a></span>). <b>Note: </b>Only recommended in adolescents with CD4 cell count &lt;150 cells/mm<sup>3</sup> who are at high risk due to occupational exposure or residency in a community with hyperendemic histoplasmosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Secondary prophylaxis (chronic maintenance therapy): <b>Note: </b>Not necessary in all patients; see guidelines for details (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2022','lexi-content-ref-HHS.1','lexi-content-ref-17806045']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2022','lexi-content-ref-HHS.1','lexi-content-ref-17806045'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Patients with HIV</i>: Infants, Children, and Adolescents: Oral solution (preferred): Oral: 5 to 10 mg/kg/dose once daily; maximum dose: 200 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2022','lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2022','lexi-content-ref-HHS.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Patients without HIV</i>: Infants, Children, and Adolescents: Oral: 5 mg/kg/dose once daily; maximum dose: 200 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30076688','lexi-content-ref-17806045']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30076688','lexi-content-ref-17806045'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="968ddf31-cac0-4014-bcb7-892c246177ba">Microsporidiosis, disseminated disease caused by Trachipleistophora or Anncaliia, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Microsporidiosis, disseminated disease caused by</b>
<i>
<b>Trachipleistophora</b></i>
<b>or</b>
<i>
<b>Anncaliia</b></i>
<b>, treatment:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents with HIV: Oral: 400 mg once daily in combination with albendazole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2022'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b3eb7406-2279-4fb2-ad39-e978257861e9">Sporotrichosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sporotrichosis:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Lymphocutaneous or localized cutaneous:</i> Oral solution (preferred): Oral: 3 to 5 mg/kg/dose every 12 hours; maximum dose: 200 mg/dose. Continue for 2 to 4 weeks after all lesions have resolved; usual total duration: 3 to 6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17968818','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17968818','lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Step-down therapy, visceral or disseminated (after initial treatment and clinical response with amphotericin B):</i> Oral solution (preferred): Oral: 3 to 5 mg/kg/dose every 12 hours; maximum dose: 200 mg/dose. Continue for ≥12 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17968818','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17968818','lexi-content-ref-AAP.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="49121186-131c-4432-bbd1-93622f3f65b6">Talaromycosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Talaromycosis (formerly penicilliosis):</b> Patients with HIV: Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Primary prophylaxis:</i>
<b>Note:</b> Only recommended for patients residing in or traveling to highly endemic areas in northern Thailand, Vietnam, or Southern China with CD4 cell count &lt;100 cells/mm<sup>3</sup> and who are unable to access effective antiretroviral therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents: Oral: 200 mg once daily. For residents of highly endemic areas, continue until CD4 count &gt;100 cells/mm<sup>3</sup> and virologic suppression with antiretroviral therapy has been sustained for ≥6 months. For travelers, begin prophylaxis 3 days prior to travel and continue through 1 week after leaving the endemic area (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment (consolidation): </i>Adolescents: Oral: 200 mg every 12 hours for 10 weeks; initiate after completion of amphotericin B induction therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Secondary prophylaxis (chronic maintenance therapy):</i> Adolescents: Oral: 200 mg once daily. May consider discontinuation when CD4 cell count &gt;100 cells/mm<sup>3</sup> and virologic suppression with antiretroviral therapy has been sustained for ≥6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2022'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c2b44e72-c508-46fe-b538-5b3b685f7a46">Tinea capitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tinea capitis (alternative agent):</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Continuous regimen:</i> Infants, Children, and Adolescents: Oral: 5 mg/kg/dose once daily; maximum dose: 200 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19453785','lexi-content-ref-25234064','lexi-content-ref-15283801','lexi-content-ref-1737692','lexi-content-ref-Gupta.1','lexi-content-ref-32026639']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19453785','lexi-content-ref-25234064','lexi-content-ref-15283801','lexi-content-ref-1737692','lexi-content-ref-Gupta.1','lexi-content-ref-32026639'])">Ref</a></span>). If using oral solution, some experts recommend a lower dose of 3 mg/kg/dose daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20609140','lexi-content-ref-AAP.1','lexi-content-ref-15792111']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20609140','lexi-content-ref-AAP.1','lexi-content-ref-15792111'])">Ref</a></span>). Duration of therapy is typically 2 to 6 weeks; up to 12 weeks may be necessary, particularly with <i>Microsporum canis</i> infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15283801','lexi-content-ref-1737692','lexi-content-ref-Gupta.1','lexi-content-ref-18478357','lexi-content-ref-32897584','lexi-content-ref-20609140','lexi-content-ref-32026639']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15283801','lexi-content-ref-1737692','lexi-content-ref-Gupta.1','lexi-content-ref-18478357','lexi-content-ref-32897584','lexi-content-ref-20609140','lexi-content-ref-32026639'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pulse regimen:</i> Infants, Children, and Adolescents: Oral: 5 mg/kg/day once daily for 1 to 3 one-week treatment pulses, with 2 weeks between the first and second pulse and 3 weeks between the second and third pulse. Doses may be divided twice daily for tolerability; maximum daily dose: 400 mg/<b>day</b>. Clinically evaluate scalp after each 1-week pulse to determine need for next pulse (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9292075','lexi-content-ref-9764158','lexi-content-ref-9704832','lexi-content-ref-18478357','lexi-content-ref-20609140']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9292075','lexi-content-ref-9764158','lexi-content-ref-9704832','lexi-content-ref-18478357','lexi-content-ref-20609140'])">Ref</a></span>). If using oral solution, a lower dose of 3 mg/kg/dose daily has been recommended by some experts (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9764158','lexi-content-ref-18478357','lexi-content-ref-20609140','lexi-content-ref-AAP.1','lexi-content-ref-15792111']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9764158','lexi-content-ref-18478357','lexi-content-ref-20609140','lexi-content-ref-AAP.1','lexi-content-ref-15792111'])">Ref</a></span>). A pulse regimen of 1 week of itraconazole treatment per month for 2 to 4 months (ie, 3 weeks off in between pulses) may also be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18478357','lexi-content-ref-15792111']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18478357','lexi-content-ref-15792111'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51128360"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Nondialyzable. The manufacturer's labeling states to use with caution in patients with renal impairment; dosage adjustment may be needed. In adults, limited data suggest that no dosage adjustments are required in renal impairment; therapeutic drug monitoring should be utilized for dose adjustment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2847635','lexi-content-ref-15273137','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2847635','lexi-content-ref-15273137','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
<div class="block dohp drugH1Div" id="F51128361"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, use caution and monitor closely for signs/symptoms of toxicity.</p></div>
<div class="block doa drugH1Div" id="F185425"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8586" href="/d/html/8586.html" rel="external">see "Itraconazole: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> For most indications, adjust dose based on trough serum concentration to ensure efficacy and avoid toxicity. Timing and frequency of concentration monitoring is individualized (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2020','lexi-content-ref-18462107','lexi-content-ref-27365388','lexi-content-ref-17806045']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2020','lexi-content-ref-18462107','lexi-content-ref-27365388','lexi-content-ref-17806045'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information: </b>Due to differences in bioavailability, itraconazole formulations are not interchangeable. Generally, the oral solution is preferred because of improved absorption (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9661037','lexi-content-ref-17631506','lexi-content-ref-HHS.2020','lexi-content-ref-17968818','lexi-content-ref-27365388']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9661037','lexi-content-ref-17631506','lexi-content-ref-HHS.2020','lexi-content-ref-17968818','lexi-content-ref-27365388'])">Ref</a></span>) Tolsura (65 mg capsule) is dosed differently than other formulations.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="11922a6f-52e3-4d48-8959-25f730e3f929">Aspergillosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Aspergillosis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Allergic bronchopulmonary:</i>
<b>Oral:</b> Solution or capsule (100 mg): 200 mg twice daily for ≥16 weeks in combination with systemic corticosteroids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Akuthota.1','lexi-content-ref-27365388','lexi-content-ref-10717010','lexi-content-ref-12743557']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Akuthota.1','lexi-content-ref-27365388','lexi-content-ref-10717010','lexi-content-ref-12743557'])">Ref</a></span>); may give a loading dose of 200 mg 3 times daily for the first 3 days of therapy. <b>Note:</b> Some experts reserve for patients who are unable to taper corticosteroids or have an exacerbation of allergic bronchopulmonary aspergillosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Akuthota.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Akuthota.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Chronic cavitary pulmonary:</i>
<b>Oral:</b> Solution or capsule (100 mg): 200 mg twice daily for ≥6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23496375','lexi-content-ref-27365388']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23496375','lexi-content-ref-27365388'])">Ref</a></span>); some patients require prolonged, potentially lifelong therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kauffman.3','lexi-content-ref-27365388']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kauffman.3','lexi-content-ref-27365388'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Invasive (alternative agent): </i>
<b>Note: </b>Itraconazole is generally not recommended; reserve for patients with mild disease when other therapies are unavailable or cannot be used (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30900296','lexi-content-ref-27365388']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30900296','lexi-content-ref-27365388'])">Ref</a></span>). <b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Solution (preferred) or capsule (100 mg): 200 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11550120','lexi-content-ref-8059779','lexi-content-ref-27365388']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11550120','lexi-content-ref-8059779','lexi-content-ref-27365388'])">Ref</a></span>); may give a loading dose of 200 mg 3 times daily for the first 3 days of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8059779','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8059779','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Capsule (65 mg): 130 mg once or twice daily; may give a loading dose of 130 mg 3 times daily for the first 3 days of therapy.</p>
<p style="text-indent:-2em;margin-left:6em;">Duration: Minimum of 6 to 12 weeks, depending on degree/duration of immunosuppression, disease site, and response to therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27365388']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27365388'])">Ref</a></span>); immunosuppressed patients may require more prolonged treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30900296','lexi-content-ref-Patterson.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30900296','lexi-content-ref-Patterson.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6323927f-8b2e-4468-8728-4b7efd61e9f7">Blastomycosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Blastomycosis: </b></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>For initial treatment of mild to moderate disease or step-down therapy after amphotericin B for more severe infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18462107']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18462107'])">Ref</a></span>): <b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Solution or capsule (100 mg):</p>
<p style="text-indent:-2em;margin-left:6em;">Loading dose: 200 mg 3 times daily for 3 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18462107']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18462107'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance dose:</p>
<p style="text-indent:-2em;margin-left:8em;">Mild to moderate disease in immunocompetent patients: 200 mg once to twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1332471','lexi-content-ref-18462107']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1332471','lexi-content-ref-18462107'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Moderately severe to severe disease and immunocompromised patients: 200 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30924967','lexi-content-ref-1332471','lexi-content-ref-18462107']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30924967','lexi-content-ref-1332471','lexi-content-ref-18462107'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">CNS infection (alternative agent): 200 mg 2 to 3 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradsher.1','lexi-content-ref-18462107']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradsher.1','lexi-content-ref-18462107'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Capsule (65 mg): 130 mg once daily; if no improvement or if there is evidence of progressive fungal infection, increase dose in 65 mg increments to a maximum of 260 mg/day (doses &gt;130 mg/day should be given in 2 divided doses). May give a loading dose of 130 mg 3 times daily for the first 3 days of therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">Duration: 6 to 12 months; ≥12 months is recommended for patients with moderately severe to severe disseminated infection, osteoarticular or CNS infection, and for all immunocompromised patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30924967','lexi-content-ref-Bradsher.1','lexi-content-ref-18462107']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30924967','lexi-content-ref-Bradsher.1','lexi-content-ref-18462107'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a474b86d-f618-403c-abc4-11a9a731c6ce">Candidiasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Candidiasis: </b></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>Generally reserved for fluconazole-refractory disease or as an alternative initial agent. Capsule formulation is not recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31155770','lexi-content-ref-HHS.2020','lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31155770','lexi-content-ref-HHS.2020','lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Esophageal:</i>
<b>Oral:</b> Solution: 200 mg once daily for 14 to 28 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31155770','lexi-content-ref-HHS.2020','lexi-content-ref-26679628','lexi-content-ref-Kauffman.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31155770','lexi-content-ref-HHS.2020','lexi-content-ref-26679628','lexi-content-ref-Kauffman.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Oropharyngeal:</i>
<b>Oral:</b> Solution: 200 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31155770','lexi-content-ref-HHS.2020','lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31155770','lexi-content-ref-HHS.2020','lexi-content-ref-26679628'])">Ref</a></span>). Duration is 7 to 14 days for initial therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2020'])">Ref</a></span>) or up to 28 days for refractory disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31155770','lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31155770','lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Vulvovaginal (uncomplicated) in patients with HIV (alternative agent) (off-label use):</i>
<b>Oral:</b> Solution: 200 mg once daily for 3 to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2020'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3b00d09b-403f-403b-bcd2-8c804ff3cf2d">Coccidioidomycosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Coccidioidomycosis (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>Initial parenteral antifungal therapy is warranted for severe disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2020','lexi-content-ref-27470238']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2020','lexi-content-ref-27470238'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Bone and/or joint infection:</i>
<b>Oral:</b> Solution or capsule (100 mg): 200 mg twice daily for ≥3 years; in some cases, lifelong treatment is needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2020','lexi-content-ref-27470238']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2020','lexi-content-ref-27470238'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Meningitis (alternative agent): </i>
<b>Oral:</b> Solution or capsule (100 mg): 200 mg 2 to 4 times daily. Duration is lifelong because of the high relapse rate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2020','lexi-content-ref-27470238']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2020','lexi-content-ref-27470238'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pneumonia, primary infection: </i>
<b>Note:</b> Reserve treatment for patients with or at risk for severe disease (eg, extensive pulmonary involvement, patients who are immunocompromised) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2020','lexi-content-ref-27470238']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2020','lexi-content-ref-27470238'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Solution or capsule (100 mg): 200 mg twice daily; for severe disease, use in combination with initial therapy with amphotericin B. Duration is typically 3 to 6 months, but can vary depending on comorbid conditions, severity of disease, and response to therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Blair.1','lexi-content-ref-HHS.2020','lexi-content-ref-27470238']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Blair.1','lexi-content-ref-HHS.2020','lexi-content-ref-27470238'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pneumonia, symptomatic chronic cavitary and/or cavitary disease in patients who are immunocompromised:</i>
<b>Oral:</b> Solution or capsule (100 mg): 200 mg twice daily for ≥12 months. In patients with ruptured cavities, the duration may be shorter, but depends on postoperative course (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27470238','lexi-content-ref-Jaroszewski.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27470238','lexi-content-ref-Jaroszewski.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Soft tissue infection (not associated with bone infection):</i>
<b>Oral:</b> Solution or capsule (100 mg): 200 mg twice daily for at least 6 to 12 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27470238']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27470238'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="da0b3cae-9a59-4ae8-9ed2-c6aad13abf2e">Histoplasmosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Histoplasmosis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment, initial therapy for mild to moderate disease or step-down therapy after amphotericin B for more severe infection: </i>
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Solution or capsule (100 mg):</p>
<p style="text-indent:-2em;margin-left:8em;">Loading dose: 200 mg 3 times daily for 3 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17806045']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17806045'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Maintenance dose:</p>
<p style="text-indent:-2em;margin-left:10em;">Mild to moderate disease in immunocompetent patients: 200 mg once to twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1332471','lexi-content-ref-17806045']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1332471','lexi-content-ref-17806045'])">Ref</a></span>); some experts favor 200 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kauffman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kauffman.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">Moderately severe to severe or disseminated disease and immunocompromised patients: 200 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30924967','lexi-content-ref-HHS.2020','lexi-content-ref-17806045']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30924967','lexi-content-ref-HHS.2020','lexi-content-ref-17806045'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">CNS infection: 200 mg 2 to 3 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2020','lexi-content-ref-17806045']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2020','lexi-content-ref-17806045'])">Ref</a></span>); some experts favor 200 mg 3 times daily for patients with HIV and CNS infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Baddley.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Baddley.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Capsule (65 mg): 130 mg once daily; if no improvement or if there is evidence of progressive fungal infection, increase dose in 65 mg increments to a maximum of 260 mg/day (doses &gt;130 mg/day should be given in 2 divided doses). May give a loading dose of 130 mg 3 times daily for the first 3 days of therapy.</p>
<p style="text-indent:-2em;margin-left:6em;">Duration: 6 to 12 weeks for mild to moderate pulmonary infection and ≥12 weeks for moderately severe to severe pulmonary infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17806045']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17806045'])">Ref</a></span>); ≥12 months for immunocompromised patients and/or patients with CNS, chronic cavitary pulmonary, or disseminated infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30924967','lexi-content-ref-Baddley.1','lexi-content-ref-17806045','lexi-content-ref-Kauffman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30924967','lexi-content-ref-Baddley.1','lexi-content-ref-17806045','lexi-content-ref-Kauffman.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Long-term suppression therapy (secondary prophylaxis) in select immunocompromised patients: Solution or capsule (100 mg): 200 mg once to twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30924967','lexi-content-ref-HHS.2020','lexi-content-ref-Kauffman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30924967','lexi-content-ref-HHS.2020','lexi-content-ref-Kauffman.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prophylaxis, primary prophylaxis in patients with HIV (off-label use): </i>
<b>Note:</b> Not routinely given (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Baddley.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Baddley.1'])">Ref</a></span>); some experts recommend primary prophylaxis in patients with CD4 count &lt;150 cells/mm<sup>3</sup> and increased risk due to occupational exposure or residence in a hyperendemic area (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Solution or capsule (100 mg): 200 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2020','lexi-content-ref-10452633']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2020','lexi-content-ref-10452633'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="64502832-afb2-4634-b4cc-9964152e6c0b">Onychomycosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Onychomycosis (alternative agent): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For dermatophyte onychomycosis, reserve for patients unable to take preferred agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25409999','lexi-content-ref-Goldstein.1','lexi-content-ref-28707751']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25409999','lexi-content-ref-Goldstein.1','lexi-content-ref-28707751'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Capsule (100 mg):</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Continuous dosing: </i>200 mg once daily for 6 weeks (fingernail [off-label use]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Goldstein.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Goldstein.1'])">Ref</a></span>) or 12 weeks (toenail) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10384922']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10384922'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Pulsed dosing:</i> 200 mg twice daily for 1 week; repeat every 4 weeks for 2 months (fingernail) or 3 months (toenail). <b>Note:</b> For toenail onychomycosis, some data suggest higher cure rates after 6 months compared to 3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25409999','lexi-content-ref-29893422']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25409999','lexi-content-ref-29893422'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3304e169-3a5d-4e8f-9216-6f88bfcc7347">Paracoccidioidomycosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Paracoccidioidomycosis (off-label use): Note:</b> For initial treatment of mild to moderate infection or step-down therapy following initial intravenous therapy for severe infection.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Solution or capsule (100 mg): 100 to 200 mg once daily. Duration is generally 6 to 12 months but may be &gt;2 years for severe disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24577007','lexi-content-ref-Nucci.2020','lexi-content-ref-28746570','lexi-content-ref-Sporanox.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24577007','lexi-content-ref-Nucci.2020','lexi-content-ref-28746570','lexi-content-ref-Sporanox.2'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c68abc8a-b79f-4368-a4bf-6161f16dfcf1">Prophylaxis against invasive fungal infections</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prophylaxis against invasive fungal infections (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Chronic granulomatous disease:</i>
<b>Oral:</b> Solution or capsule (100 mg): 200 mg once daily; duration is lifelong (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12802027','lexi-content-ref-Marciano.1','lexi-content-ref-25614174']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12802027','lexi-content-ref-Marciano.1','lexi-content-ref-25614174'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hematologic malignancy or hematopoietic cell transplant (alternative agent for prophylaxis against Candida spp.):</i>
<b>Oral:</b> Solution: 200 mg twice daily. Duration varies based on degree and duration of immunosuppression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19747629','lexi-content-ref-30179565','lexi-content-ref-16339606','lexi-content-ref-9669686','lexi-content-ref-Wingard.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19747629','lexi-content-ref-30179565','lexi-content-ref-16339606','lexi-content-ref-9669686','lexi-content-ref-Wingard.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Solid organ transplant, select patients (eg, lung transplant recipients) (alternative agent):</i>
<b>Oral:</b> Solution: 200 mg twice daily; duration varies by patient risk factors and among transplant centers (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30900296','lexi-content-ref-19645709','lexi-content-ref-Fishman.1','lexi-content-ref-21158923']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30900296','lexi-content-ref-19645709','lexi-content-ref-Fishman.1','lexi-content-ref-21158923'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b3eb7406-2279-4fb2-ad39-e978257861e9">Sporotrichosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sporotrichosis (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cutaneous or lymphocutaneous infection: </i>
<b>Oral:</b> Solution or capsule (100 mg):</p>
<p style="text-indent:-2em;margin-left:6em;">Initial therapy: 100 to 200 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21628477','lexi-content-ref-Kauffman.4']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21628477','lexi-content-ref-Kauffman.4'])">Ref</a></span>); some experts favor 200 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kauffman.4','lexi-content-ref-17968818']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kauffman.4','lexi-content-ref-17968818'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Refractory to daily itraconazole: 200 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17968818']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17968818'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Duration: 2 to 4 weeks after lesion resolution, usually for a total of 3 to 6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17968818']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17968818'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Extracutaneous infection:</i>
<b>Note:</b> Initial therapy with amphotericin B is recommended for patients with disseminated, meningeal, or severe pulmonary infection.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Solution or capsule (100 mg): 200 mg twice daily for ≥1 year (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17968818']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17968818'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="49121186-131c-4432-bbd1-93622f3f65b6">Talaromycosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Talaromycosis (formerly penicilliosis) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment: </i>
<b>Oral:</b> Solution or capsule (100 mg):</p>
<p style="text-indent:-2em;margin-left:6em;">Mild disease (skin lesions without bloodstream infection): 200 mg 3 times daily for 3 days, then 200 mg twice daily for 8 to 12 weeks, then continue with long-term suppression therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28614691','lexi-content-ref-Supparatpinyo.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28614691','lexi-content-ref-Supparatpinyo.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Moderate to severe disease, oral step-down therapy after initial amphotericin B: 200 mg 3 times daily for 3 days, then 200 mg twice daily for 10 weeks, then continue with long-term suppression therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2020','lexi-content-ref-9597237','lexi-content-ref-Supparatpinyo.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2020','lexi-content-ref-9597237','lexi-content-ref-Supparatpinyo.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Long-term suppression therapy (secondary prophylaxis): 200 mg once daily until cellular immunity is restored (for patients with HIV, can be discontinued once CD4 count &gt;100 cells/mm<sup>3</sup> and virologic suppression with antiretroviral therapy has been sustained for ≥6 months) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2020','lexi-content-ref-Supparatpinyo.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2020','lexi-content-ref-Supparatpinyo.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prophylaxis, primary, for patients with HIV and CD4 cell count &lt;100 cells/mm<sup>3</sup> who are not starting antiretroviral therapy and reside in or travel to highly endemic areas in northern Thailand, Vietnam, and Southern China: </i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Solution or capsule (100 mg): 200 mg once daily; for residents of highly endemic areas, continue until CD4 count &gt;100 cells/mm<sup>3</sup> and virologic suppression with antiretroviral therapy has been sustained for ≥6 months; for travelers, begin prophylaxis 3 days prior to travel and continue for 1 week after travel (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2020'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="15c0a5bc-b04b-4bce-808a-eba28afcd673">Tinea infections</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tinea infections (alternative agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Fungal folliculitis:</i>
<b>Oral:</b> Solution or capsule (100 mg):</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Malassezia folliculitis:</i> 200 mg once daily for 1 to 3 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24556907','lexi-content-ref-9784054']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24556907','lexi-content-ref-9784054'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Dermatophyte folliculitis (tinea barbae, Majocchi granuloma):</i> 200 mg twice daily for 1 week; repeat 1-week course up to 2 times, each after 2- to 3-week off time (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9861736','lexi-content-ref-Jackson.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9861736','lexi-content-ref-Jackson.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Tinea corporis/tinea cruris:</i>
<b>Note:</b> For disease that is extensive or refractory to topical therapy.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Solution or capsule (100 mg): 200 mg once daily for 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9919895','lexi-content-ref-Goldstein.2020a']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9919895','lexi-content-ref-Goldstein.2020a'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Tinea pedis/tinea manuum:</i>
<b>Note:</b> For disease that is extensive or refractory to topical therapy.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Solution or capsule (100 mg): 200 mg twice daily for 1 week (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Goldstein.2020a','lexi-content-ref-9919896']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Goldstein.2020a','lexi-content-ref-9919896'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Tinea versicolor (pityriasis versicolor):</i>
<b>Note:</b> For disease that is extensive or refractory to topical therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8642095','lexi-content-ref-12956196']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8642095','lexi-content-ref-12956196'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Solution or capsule (100 mg): 200 mg once daily for 5 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Goldstein.2020b','lexi-content-ref-24636433']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Goldstein.2020b','lexi-content-ref-24636433'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990817"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: No dosage adjustment necessary for any degree of kidney dysfunction; adjust dose based on trough serum concentrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2847635','lexi-content-ref-DOR.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2847635','lexi-content-ref-DOR.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m<sup>2</sup>):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Augmented renal clearance (ARC) is a condition that occurs in certain critically ill patients without organ dysfunction and with normal serum creatinine concentrations. Younger patients (&lt;55 years of age) admitted post trauma or major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematologic malignancies. An 8- to 24-hour measured urinary CrCl is necessary to identify these patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29441476','lexi-content-ref-20000886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29441476','lexi-content-ref-20000886'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: No dosage adjustment necessary; adjust dose based on trough serum concentrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-DOR.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-DOR.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Not dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2847635','lexi-content-ref-15273137']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2847635','lexi-content-ref-15273137'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: No supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15273137']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15273137'])">Ref</a></span>); adjust dose based on trough serum concentrations.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Not dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2847635']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2847635'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2847635','lexi-content-ref-DOR.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2847635','lexi-content-ref-DOR.1'])">Ref</a></span>); adjust dose based on trough serum concentrations.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (or ~1,500 to 3,000 mL/hour) and minimal residual kidney function unless otherwise noted. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of infection) and consideration of initial loading doses. Close monitoring of response and adverse reactions (eg, cardiac, fluid-related issues) due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: No dosage adjustment necessary; adjust dose based on trough concentrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7829423','lexi-content-ref-DOR.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7829423','lexi-content-ref-DOR.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of infection) and consideration of initial loading doses. Close monitoring of response and adverse reactions (eg, cardiac, fluid-related issues) due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: No dosage adjustment necessary; adjust dose based on trough concentrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-DOR.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-DOR.1'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988024"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, use caution and monitor closely for signs/symptoms of toxicity.</p></div>
<div class="block arsc drugH1Div" id="F58706062"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Cardiovascular effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Itraconazole is associated with cardiovascular effects, including new or worsening <b>hypertension</b>, new or worsening <b>heart failure</b> (HF), prolonged <b>QT interval on ECG</b>
<b>, </b>and <b>torsades de pointes</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11403818','lexi-content-ref-18591345','lexi-content-ref-23677844','lexi-content-ref-21930637','lexi-content-ref-28400399','lexi-content-ref-29644223','lexi-content-ref-33083707','lexi-content-ref-35308776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11403818','lexi-content-ref-18591345','lexi-content-ref-23677844','lexi-content-ref-21930637','lexi-content-ref-28400399','lexi-content-ref-29644223','lexi-content-ref-33083707','lexi-content-ref-35308776'])">Ref</a></span>). Cardiovascular effects may result in hospitalization and/or death (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11403818','lexi-content-ref-18591345','lexi-content-ref-28400399','lexi-content-ref-33083707']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11403818','lexi-content-ref-18591345','lexi-content-ref-28400399','lexi-content-ref-33083707'])">Ref</a></span>). Improvement occurs with treatment and/or discontinuation in most (but not all) cases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21930637','lexi-content-ref-35308776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21930637','lexi-content-ref-35308776'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; not clearly established. Proposed mechanisms include mitochondrial dysfunction and negative inotropic effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35308776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35308776'])">Ref</a></span>). <i></i></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; HF reported 1 day to 7 months following initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11403818','lexi-content-ref-35308776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11403818','lexi-content-ref-35308776'])">Ref</a></span>). Torsades de pointes reported a median of 9.5 days (range 1 to 26 days) following initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29644223']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29644223'])">Ref</a></span>). <i></i></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (eg, &gt;400 mg/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35308776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35308776'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hypertension or use of antihypertensives (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11403818']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11403818'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of HF or impaired left ventricular function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11403818','lexi-content-ref-21930637']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11403818','lexi-content-ref-21930637'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Cardiovascular disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11403818']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11403818'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Valvular heart disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11403818']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11403818'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent treatment with other medications known to be associated with QT-prolongation or concurrent interacting medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29644223']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29644223'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hepatotoxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Azole antifungals, including itraconazole, may cause hepatotoxicity (ranging from mild, asymptomatic increased serum transaminases to <b>hepatic failure</b>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27927037','lexi-content-ref-26597673','lexi-content-ref-26291595','lexi-content-ref-15752292','lexi-content-ref-18523232']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27927037','lexi-content-ref-26597673','lexi-content-ref-26291595','lexi-content-ref-15752292','lexi-content-ref-18523232'])">Ref</a></span>). Hepatotoxicity is predominantly cholestatic, but cases of hepatocellular damage have also been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31093949','lexi-content-ref-26291595','lexi-content-ref-15752292','lexi-content-ref-18523232']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31093949','lexi-content-ref-26291595','lexi-content-ref-15752292','lexi-content-ref-18523232'])">Ref</a></span>). If intervention is required, liver injury is generally reversible within ~2 weeks after dose reduction or discontinuation but may recur upon rechallenge (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31093949']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31093949'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Not clearly established; possible mechanisms include inhibition of CYP450 enzymes, leading to decreased metabolism/use of alternative pathways that are more hepatotoxic or a true hypersensitivity reaction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31093949','lexi-content-ref-20130764','lexi-content-ref-15752292']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31093949','lexi-content-ref-20130764','lexi-content-ref-15752292'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; most cases occur within the first month of therapy (but may occur at any time) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31093949']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31093949'])">Ref</a></span>). Most cases occur with long-term, continuous use; rare cases have been reported with prolonged, pulse therapy (&gt;12 weeks) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31093949','lexi-content-ref-18523232']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31093949','lexi-content-ref-18523232'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Trough concentrations (≥1 mg/L) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30197526']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30197526'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting liver disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31093949','lexi-content-ref-26597673','lexi-content-ref-30544724']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31093949','lexi-content-ref-26597673','lexi-content-ref-30544724'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent hepatotoxic agents and drug interactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31093949']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31093949'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Fungal infection located within the liver (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31093949']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31093949'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Patients of Japanese descent may be more at risk, secondary to higher prevalence of CYP2C19 genetic polymorphisms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31093949']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31093949'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Cross-reactivity among oral azole antifungals has not been consistently reported in patients with histories of hepatotoxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31093949','lexi-content-ref-27430151']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31093949','lexi-content-ref-27430151'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity effects (immediate and delayed)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Immediate hypersensitivity reactions have been reported and include <b>urticaria</b>
<b>, angioedema,</b>
<b>anaphylaxis</b>
<b>, </b>and <b>anaphylactic shock</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19261964','lexi-content-ref-14616112']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19261964','lexi-content-ref-14616112'])">Ref</a></span>). Delayed hypersensitivity reactions have also been reported and range from an <b>erythematous rash</b> or <b>morbilliform rash</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8064084','lexi-content-ref-9042060','lexi-content-ref-10721851','lexi-content-ref-9418771']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8064084','lexi-content-ref-9042060','lexi-content-ref-10721851','lexi-content-ref-9418771'])">Ref</a></span>) to severe cutaneous adverse reactions (SCARs), including <b>Stevens-Johnson syndrome</b> (SJS) and <b>toxic epidermal necrolysis</b> (TEN), and <b>acute generalized exanthematous pustulosis</b> (AGEP) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20055840','lexi-content-ref-32959476','lexi-content-ref-27028785','lexi-content-ref-9146550']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20055840','lexi-content-ref-32959476','lexi-content-ref-27028785','lexi-content-ref-9146550'])">Ref</a></span>). Other delayed hypersensitivity reactions include <b>serum sickness-like reaction</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9825096']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9825096'])">Ref</a></span>), <b>fixed drug eruption</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31085618','lexi-content-ref-18478357']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31085618','lexi-content-ref-18478357'])">Ref</a></span>), <b>skin photosensitivity</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11444275']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11444275'])">Ref</a></span>) and symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32594647','lexi-content-ref-32767394']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32594647','lexi-content-ref-32767394'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Non–dose-related; immunologic. Immediate hypersensitivity reactions (eg, anaphylaxis, urticaria) are IgE-mediated. Delayed hypersensitivity reactions, including rash and SCARs, are T-cell-mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872','lexi-content-ref-26339470']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872','lexi-content-ref-26339470'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Immediate hypersensitivity reactions: Rapid; occur within 1 hour of administration but may occur up to 6 hours after exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872'])">Ref</a></span>); anaphylactic shock has been reported after 2 weeks of itraconazole treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19261964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19261964'])">Ref</a></span>). Delayed hypersensitivity reactions: Non-specific rash: Intermediate; occur within a week after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8064084','lexi-content-ref-9042060']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8064084','lexi-content-ref-9042060'])">Ref</a></span>). Other reactions (including SCARs): Varied; occur after 7 to 14 days up to 3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872','lexi-content-ref-26120552','lexi-content-ref-NICE.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872','lexi-content-ref-26120552','lexi-content-ref-NICE.1'])">Ref</a></span>); in some patients, may occur within 24 hours after completion of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27028785']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27028785'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Cross-reactivity: Cross-reactivity among oral azole antifungals has not been consistently reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27430151']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27430151'])">Ref</a></span>). Possible cross-reactivity between fluconazole and itraconazole has been suggested (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18280361']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18280361'])">Ref</a></span>). However, lack of cross-reactivity has been documented between itraconazole and fluconazole, as well as between itraconazole and ketoconazole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18779889','lexi-content-ref-33904684','lexi-content-ref-14616112','lexi-content-ref-30829805']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18779889','lexi-content-ref-33904684','lexi-content-ref-14616112','lexi-content-ref-30829805'])">Ref</a></span>). In addition, no cross-reactivity was noted between itraconazole and voriconazole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27430151','lexi-content-ref-28017630']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27430151','lexi-content-ref-28017630'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypokalemia/pseudoaldosteronism</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Itraconazole is associated with metabolic-related adverse reactions, including <b>hypokalemia</b>
<b>, hypertension,</b> and <b>pseudoaldosteronism</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31982514','lexi-content-ref-31093949','lexi-content-ref-34144953','lexi-content-ref-29385285','lexi-content-ref-1648887','lexi-content-ref-2174854']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31982514','lexi-content-ref-31093949','lexi-content-ref-34144953','lexi-content-ref-29385285','lexi-content-ref-1648887','lexi-content-ref-2174854'])">Ref</a></span>). Metabolic-related adverse reactions are often considered class-related effects, more often observed with itraconazole and posaconazole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31982514']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31982514'])">Ref</a></span>). Resolution occurs following discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29385285']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29385285'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Possibly dose-related; hypothesized to occur primarily due to cortisol-induced mineralocorticoid receptor activation due to 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) enzyme inhibition (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31982514','lexi-content-ref-29385285']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31982514','lexi-content-ref-29385285'])">Ref</a></span>). <i></i></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; generally within first 2 weeks of therapy but may occur later (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31093949']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31093949'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (eg, 600 mg total daily dose) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31093949','lexi-content-ref-29385285']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31093949','lexi-content-ref-29385285'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent exposure to steroids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31093949']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31093949'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Peripheral neuropathy</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Itraconazole is associated with <b>peripheral neuropathy</b>, which often presents as bilateral polyneuropathy of the hands and feet (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21685202','lexi-content-ref-31093949']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21685202','lexi-content-ref-31093949'])">Ref</a></span>). Itraconazole-associated peripheral neuropathy appears to be more common than posaconazole or voriconazole-associated neuropathy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21685202']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21685202'])">Ref</a></span>). Symptoms often resolve following discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31093949','lexi-content-ref-21477327']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31093949','lexi-content-ref-21477327'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Unknown; hypothesized to be caused by the azole moiety (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31093949']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31093949'])">Ref</a></span>). <i></i></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; median 3 months (range 1 to 18 months) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21685202']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21685202'])">Ref</a></span>). <i></i></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent calcineurin inhibitors, vinca alkaloids or other drug interactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31093949','lexi-content-ref-20575631']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31093949','lexi-content-ref-20575631'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Other possible risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher drug concentrations, although may occur in patients with drug concentrations within the therapeutic range (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21685202']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21685202'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Long-term therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21685202']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21685202'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F185387"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Gastrointestinal: Nausea (3% to 11%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain (3%), edema (4%), hypertension (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis (4%), pruritus (3% to 5%), skin rash (3% to 9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Adrenocortical insufficiency (&lt;2%), albuminuria (1%), decreased libido (1%), dehydration (&lt;2%), gynecomastia (&lt;2%), hot flash (&lt;2%), hypertriglyceridemia (3%), hypokalemia (2%), weight loss (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (2% to 4%), anorexia (1%), aphthous stomatitis (3%), constipation (2% to 3%), diarrhea (3% to 10%), dysgeusia (&lt;2%), dyspepsia (3% to 4%), dysphagia (&lt;2%), flatulence (4%), gastritis (2%), gastroenteritis (2%), gingivitis (3%), hemorrhoids (&lt;2%), increased appetite (2%), vomiting (5% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Cystitis (3%), erectile dysfunction (1%), hematuria (&lt;2%), mastalgia (male: &lt;2%), urinary tract infection (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal liver function (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Herpes zoster (2%), infection (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal dreams (2%), anxiety (3%), asthenia (2%), depression (1% to 3%), dizziness (2% to 4%), drowsiness (1%), fatigue (1% to 3%), headache (4% to 10%), insomnia (&lt;2%), malaise (1% to 3%), pain (2% to 3%), rigors (&lt;2%), tremor (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (&lt;2%), bursitis (3%), myalgia (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Visual disturbance (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (4%), dyspnea (3%), increased bronchial secretions (3%), pharyngitis (2%), pneumonia (2%), pneumonia due to <i>Pneumocystis jirovecii</i> (2%), rhinitis (5% to 9%), sinusitis (2% to 7%), upper respiratory tract infection (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (2% to 6%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Endocrine &amp; metabolic: Menstrual disease</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension, orthostatic hypotension, tachycardia, vasculitis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Hyperhidrosis</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperglycemia, hyperkalemia, hypomagnesemia, increased lactate dehydrogenase</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hyperbilirubinemia, increased gamma-glutamyl transferase, increased serum alanine aminotransferase, increased serum alkaline phosphatase, increased serum aspartate aminotransferase, jaundice</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Facial edema</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills, confusion, vertigo, voice disorder</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased blood urea nitrogen, kidney insufficiency</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Heart failure (including worsening of heart failure) (Tsang 2022), peripheral edema, prolonged QT interval on ECG (Salem 2017), torsades de pointes (Salem 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acute generalized exanthematous pustulosis (Cancado 2009), alopecia, erythema multiforme, erythematous rash (Goto 2000), exfoliative dermatitis, fixed drug eruption (Gupta 2008), morbilliform rash (Kramer 1997), skin photosensitivity (Alvarez-Fernandez 2000), Stevens-Johnson syndrome (Das 2020), toxic epidermal necrolysis (Das 2020), urticaria (Martinez-Alonso 2003)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Pseudoaldosteronism (Beck 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Pancreatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Pollakiuria, urinary incontinence</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Leukopenia, neutropenia, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic failure (Pettit 2016), hepatitis, hepatotoxicity</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactic shock (Chen 2009), anaphylaxis (Chen 2009), angioedema (Martinez-Alonso 2003), hypersensitivity angiitis, nonimmune anaphylaxis, serum sickness, serum sickness-like reaction (Park 1998)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Hypoesthesia, paresthesia, peripheral neuropathy (Baxter 2011)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, increased creatine phosphokinase in blood specimen</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision, diplopia</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Hearing loss</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pulmonary edema</p></div>
<div class="block coi drugH1Div" id="F185401"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to itraconazole or any component of the formulation; concurrent administration with avanafil, cisapride, disopyramide, dofetilide, dronedarone, eplerenone, ergot derivatives, felodipine, finerenone, irinotecan, isavuconazole, ivabradine, lomitapide, lovastatin, lurasidone, methadone, midazolam (oral), naloxegol, nisoldipine, pimozide, quinidine, ranolazine, simvastatin, ticagrelor, triazolam, or voclosporin; concurrent administration with colchicine, fesoterodine, or solifenacin in patients with varying degrees of renal or hepatic impairment; coadministration with eliglustat in patients who are poor or intermediate metabolizers of CYP2D6 and in patients taking strong or moderate CYP2D6 inhibitors; coadministration with venetoclax in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma during the dose initiation and ramp-up phase of venetoclax; treatment of onychomycosis (or other non-life-threatening indications) in patients with evidence of ventricular dysfunction, such as congestive heart failure (CHF) or a history of CHF; treatment of onychomycosis in women who are pregnant or contemplating pregnancy.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Concurrent administration with apixaban, asunaprevir, domperidone, eletriptan, fesoterodine in patients with moderate to severe renal or hepatic impairment, rivaroxaban, or solifenacin in patients with severe renal impairment or moderate to severe hepatic impairment (capsule, oral solution); treatment of dermatomycosis (tinea pedis, tinea cruris, tinea corporis, tinea versicolor [pityriasis versicolor]) in women who are pregnant or intend to become pregnant (capsule).</p></div>
<div class="block war drugH1Div" id="F185384"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery, driving).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hearing loss: Transient or permanent hearing loss has been reported. Quinidine (a contraindicated drug) was used concurrently in several of these cases. Hearing loss usually resolves after discontinuation, but may persist in some patients.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cystic fibrosis: Large differences in itraconazole pharmacokinetic parameters have been observed in cystic fibrosis patients receiving the oral solution; if a patient with cystic fibrosis does not respond to therapy, alternate therapies should be considered.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; monitor liver function closely. Not recommended for use in patients with active liver disease, elevated liver enzymes, or prior hepatotoxic reactions to other drugs unless the expected benefit exceeds the risk of hepatotoxicity.</p>
<p style="text-indent:-2em;margin-left:4em;">• Onychomycosis: <b>[US Boxed Warning]: Use is contraindicated for treatment of onychomycosis in patients with ventricular dysfunction such as heart failure (HF) or a history of HF.</b> Cases of HF, peripheral edema, and pulmonary edema have occurred in this patient population. The manufacturer recommends confirmation of diagnosis testing of nail specimens prior to treatment of onychomycosis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; limited information is available; dosage adjustment may be needed.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Oral capsules (100 mg [Sporanox]): Absorption of itraconazole capsules is reduced when gastric acidity is reduced (eg, achlorhydria, acid suppressive therapy); administer with an acidic beverage (eg, non-diet cola) in patients with reduced gastric acidity and separate administration from acid suppressive therapy (refer to drug interactions section). Monitor for response.</p>
<p style="text-indent:-2em;margin-left:4em;">• Oral capsules (65 mg [Tolsura]): Absorption of itraconazole capsules is increased when gastric acidity is reduced (eg, acid suppressive therapy). Monitor for adverse reactions; itraconazole dose reduction may be necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">• Oral solution: Only the oral solution has proven efficacy in oral/esophageal candidiasis; mucosal exposure may vary between the oral solution and capsules. Initiation of treatment with oral solution is not recommended in patients at immediate risk for systemic candidiasis (eg, patients with severe neutropenia). Oral solution contains the excipient cyclodextrin.</p>
<p style="text-indent:-2em;margin-left:4em;">• Product interchangeability: Due to differences in bioavailability, formulations <b>cannot be used interchangeably</b>
<b>.</b></p>
<p style="text-indent:-2em;margin-left:4em;">• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP 1997; Zar 2007).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Itraconazole should NOT be used for voriconazole-refractory aspergillosis because the same antifungal and/or resistance mechanism(s) may be shared by both agents.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878507"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>
<div class="block foc drugH1Div" id="F185395"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sporanox: 100 mg [contains corn starch, d&amp;c red #22 (eosine), fd&amp;c blue #1 (brilliant blue), fd&amp;c blue #2 (indigotine,indigo carmine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sporanox Pulsepak: 100 mg [DSC] [contains corn starch, d&amp;c red #22 (eosine), fd&amp;c blue #1 (brilliant blue), fd&amp;c blue #2 (indigotine,indigo carmine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tolsura: 65 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sporanox: 10 mg/mL (150 mL) [contains hydroxypropyl-beta-cyclodextrin, propylene glycol, saccharin sodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg/mL (10 mL, 150 mL)</p></div>
<div class="block geq drugH1Div" id="F185380"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F185404"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Itraconazole Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $8.68 - $24.15</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Sporanox Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $33.78</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Itraconazole Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/mL (per mL): $2.31 - $2.47</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Sporanox Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/mL (per mL): $2.74</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867289"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sporanox: 100 mg [contains d&amp;c red #22 (eosine), fd&amp;c blue #1 (brilliant blue), fd&amp;c blue #2 (indigotine,indigo carmine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sporanox: 10 mg/mL ([DSC]) [contains hydroxypropyl-beta-cyclodextrin, propylene glycol, saccharin sodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg/mL (150 mL)</p></div>
<div class="block exp drugH1Div" id="F10806357"><span class="drugH1">Extemporaneous Preparations</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Commercial oral solution is available (10 mg/mL)</p>
<p style="text-indent:0em;margin-top:2em;">A 20 mg/mL oral suspension may be made with capsules. Empty the contents of forty 100 mg capsules and add 15 mL of Alcohol, USP. Let stand for 5 minutes. Crush the beads in a mortar and reduce to a fine powder. Mix while adding a 1:1 mixture of Ora-Sweet and Ora-Plus in incremental proportions to <b>almost</b> 200 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 200 mL. Label "shake well" and "refrigerate". Stable for 56 days refrigerated. </p>
<div class="reference">Nahata MC, Pai VB, and Hipple TF, <i>Pediatric Drug Formulations</i>, 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.</div>
</div>
<div class="block admp drugH1Div" id="F52613103"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Capsule and oral solution formulations are not bioequivalent and thus are not interchangeable; generally, oral solution is the preferred formulation because of improved absorption (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2022','lexi-content-ref-HHS.1','lexi-content-ref-17968818']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2022','lexi-content-ref-HHS.1','lexi-content-ref-17968818'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Capsule: Absorption is best if taken with food; therefore, it is best to administer after a full meal. Capsules should be swallowed whole.</p>
<p style="text-indent:-2em;margin-left:4em;">Solution: Should be taken on an empty stomach. When treating oropharyngeal and esophageal candidiasis, solution should be swished vigorously in mouth, then swallowed.</p></div>
<div class="block adm drugH1Div" id="F185398"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Formulations are not interchangeable; generally, oral solution is the preferred formulation because of improved absorption (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17968818','lexi-content-ref-HHS.2020','lexi-content-ref-19730409']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17968818','lexi-content-ref-HHS.2020','lexi-content-ref-19730409'])">Ref</a></span>). Administer capsule with a full meal. Oral solution should be taken on an empty stomach; when treating oropharyngeal and esophageal candidiasis, solution should be swished vigorously in mouth (10 mL at a time), then swallowed. Swallow capsule whole; do not crush, chew, or break.</p></div>
<div class="block sts drugH1Div" id="F185414"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Capsule: Store at room temperature of 15°C to 25°C (59°F to 77°F). Protect from light and moisture.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral solution: Store at ≤25°C (77°F); do not freeze.</p></div>
<div class="block usep drugH1Div" id="F53567429"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Capsules: Treatment of blastomycosis (pulmonary and extrapulmonary), histoplasmosis (including chronic cavitary pulmonary disease and disseminated, nonmeningeal disease), and aspergillosis (pulmonary and extrapulmonary) in patients who do not respond to or cannot tolerate amphotericin B (Sporanox, Tolsura: FDA approved in adults); treatment of onychomycosis of the toenail and/or fingernail due to tinea unguium in nonimmunocompromised patients (Sporanox: FDA approved in adults).</p>
<p style="text-indent:-2em;margin-left:2em;">Oral solution: Treatment of oropharyngeal or esophageal candidiasis (FDA approved in adults).</p>
<p style="text-indent:-2em;margin-left:4em;">Has also been used for treatment of allergic bronchopulmonary aspergillosis, blastomycosis, coccidioidomycosis, cryptococcal meningitis, histoplasmosis, microsporidiosis, sporotrichosis, talaromycosis (formerly penicilliosis), and tinea capitis.</p></div>
<div class="block mst drugH1Div" id="F185476"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Itraconazole may be confused with fluconazole, posaconazole, voriconazole</p>
<p style="text-indent:-2em;margin-left:4em;">Sporanox may be confused with Suprax, Topamax</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F185462"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP3A4 (strong), P-glycoprotein/ABCB1</p></div>
<div class="block dri drugH1Div" id="F185389"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abemaciclib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Abemaciclib.  Management: In patients taking abemaciclib at a dose of 200 mg or 150 mg twice daily, reduce the dose to 100 mg twice daily when combined with strong CYP3A4 inhibitors. In patients taking abemaciclib 100 mg twice daily, decrease the dose to 50 mg twice daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acalabrutinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Acalabrutinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Adagrasib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Adagrasib.  Management: Avoid use of adagrasib and strong CYP3A4 inhibitors until adagrasib concentrations have reached steady state (ie, after approximately 8 days of therapy).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ado-Trastuzumab Emtansine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Ado-Trastuzumab Emtansine. Specifically, strong CYP3A4 inhibitors may increase concentrations of the cytotoxic DM1 component.  Management: Avoid concomitant use of ado-trastuzumab emtansine and strong CYP3A4 inhibitors when possible. Consider alternatives that do not inhibit CYP3A4 or consider administering after CYP3A4 inhibitor discontinuation. Monitor for toxicities if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Afatinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Afatinib.  Management: If combined, administer the P-gp inhibitor simultaneously with, or after, the dose of afatinib. Monitor closely for signs and symptoms of afatinib toxicity and if the combination is not tolerated, reduce the afatinib dose by 10 mg.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ALfentanil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of ALfentanil.  Management: If use of alfentanil and strong CYP3A4 inhibitors is necessary, consider dosage reduction of alfentanil until stable drug effects are achieved. Frequently monitor patients for respiratory depression and sedation when these agents are combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alfuzosin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aliskiren: Itraconazole may increase the serum concentration of Aliskiren. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alitretinoin (Systemic): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alitretinoin (Systemic).  Management: Consider reducing the alitretinoin dose to 10 mg when used together with strong CYP3A4 inhibitors. Monitor for increased alitretinoin effects/toxicities if combined with a strong CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Almotriptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Almotriptan.  Management: Limit initial almotriptan dose to 6.25 mg and maximum dose to 12.5 mg in any 24-period when used with a strong CYP3A4 inhibitor. Avoid concurrent use in patients with impaired hepatic or renal function.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alosetron: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alosetron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ALPRAZolam: CYP3A4 Inhibitors (Strong) may increase the serum concentration of ALPRAZolam. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amiodarone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Amiodarone.  Management: Consider alternatives to use of amiodarone and strong CYP3A4 inhibitors. If combined, monitor for increased amiodarone concentrations and toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">AmLODIPine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of AmLODIPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antacids: May decrease the serum concentration of Itraconazole. Antacids may increase the serum concentration of Itraconazole. Management: Administer Sporanox brand itraconazole at least 2 hours before or 2 hours after administration of any antacids. Exposure to Tolsura brand itraconazole may be increased by antacids; consider itraconazole dose reduction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Apixaban: Inhibitors of CYP3A4 (Strong) and P-glycoprotein may increase the serum concentration of Apixaban.  Management: US labeling recommends a 50% apixaban dose reduction in patients who would otherwise receive 5 or 10 mg twice daily, and avoiding in patients who would otherwise receive 2.5 mg twice daily. Canadian labeling lists any combined use as contraindicated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aprepitant: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Aprepitant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole: CYP3A4 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.  Management: Aripiprazole dose reductions are required for indications other than major depressive disorder. Dose reductions vary based on formulation, initial starting dose, CYP2D6 genotype, and use of CYP2D6 inhibitors. See full interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole Lauroxil: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of ARIPiprazole Lauroxil.  Management: Decrease aripiprazole lauroxil dose to next lower strength if used with strong CYP3A4 inhibitors for over 14 days. No dose adjustment needed if using the lowest dose (441 mg). Max dose is 441 mg in CYP2D6 PMs or if also taking strong CYP2D6 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Artemether and Lumefantrine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Artemether and Lumefantrine. Specifically, concentrations of dihydroartemisinin (DHA), the active metabolite of artemether may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Artemether and Lumefantrine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asciminib: Itraconazole may decrease the serum concentration of Asciminib. Specifically, the hydroxypropyl-beta-cyclodextrin contained in oral itraconazole solution may decrease asciminib concentrations. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Astemizole: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Astemizole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asunaprevir: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Asunaprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atazanavir: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Atazanavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atogepant: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Atogepant.  Management: For treatment of episodic migraine, the recommended atogepant dose is 10 mg once daily with a concurrent strong CYP3A4 inhibitor. If used for treatment of chronic migraine, concurrent use of atogepant with strong CYP3A4 inhibitors should be avoided.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atorvastatin: Itraconazole may increase the serum concentration of Atorvastatin.  Management: Limit atorvastatin to a maximum adult dose of 20 mg/day in patients receiving itraconazole.  Assess clinical response to ensure that the lowest necessary dose of atorvastatin is used. Consider use of fluva-, rosuva-, pitava-, or pravastatin when possible.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avacopan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Avacopan.  Management: Decrease the avacopan dose to 30 mg once daily during coadministration with strong CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avanafil: Itraconazole may increase the serum concentration of Avanafil. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avapritinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Avapritinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Axitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Axitinib.  Management: Avoid concurrent use of axitinib with any strong CYP3A inhibitor whenever possible. If a strong CYP3A inhibitor must be used with axitinib, a 50% axitinib dose reduction is recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barnidipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Barnidipine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beclomethasone (Systemic): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Beclomethasone (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bedaquiline: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Bedaquiline. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bedaquiline.  Management: Limit duration of concurrent use of bedaquiline with strong CYP3A4 inhibitors to no more than 14 days, unless the benefit of continued use outweighs the possible risks. Monitor for toxic effects of bedaquiline, including QTc interval prolongation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benidipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Benidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Benperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benzhydrocodone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Benzhydrocodone. Specifically, the concentration of hydrocodone may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Berotralstat: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Berotralstat.  Management: Decrease the berotralstat dose to 110 mg daily when combined with P-glycoprotein (P-gp) inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Betamethasone (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Betamethasone (Nasal). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Betamethasone (Ophthalmic): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Betamethasone (Ophthalmic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Betamethasone (Systemic): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Betamethasone (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Betamethasone (Topical): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Betamethasone (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bilastine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bilastine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Blonanserin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bortezomib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bortezomib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bosentan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bosentan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bosutinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bosutinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brentuximab Vedotin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexpiprazole: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brexpiprazole.  Management: Reduce brexpiprazole dose 50% with strong CYP3A4 inhibitors; reduce to 25% of usual if used with both a strong CYP3A4 inhibitor and a CYP2D6 inhibitor in patients not being treated for MDD, or strong CYP3A4 inhibitor used in a CYP2D6 poor metabolizer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brigatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brigatinib.  Management: Avoid concurrent use of brigatinib with strong CYP3A4 inhibitors when possible. If combination cannot be avoided, reduce the brigatinib dose by approximately 50%, rounding to the nearest tablet strength (ie, from 180 mg to 90 mg, or from 90 mg to 60 mg).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromocriptine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bromocriptine.  Management: Consider alternatives to the use of bromocriptine with strong CYP3A4 inhibitors. If combined, monitor closely for increased bromocriptine toxicities and consider bromocriptine dose reductions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bromperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brotizolam: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brotizolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Budesonide (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Nasal). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Budesonide (Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Oral Inhalation).  Management: Consider alternatives to this combination when possible. If combined, monitor for increased corticosteroid adverse effects during coadministration of inhaled budesonide and strong CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Budesonide (Systemic): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Systemic).  Management: Avoid the concomitant use of CYP3A4 inhibitors and oral budesonide. If patients receive both budesonide and a strong CYP3A4 inhibitor, they should be closely monitored for signs and symptoms of corticosteroid excess.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Budesonide (Topical): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Buprenorphine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BusPIRone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of BusPIRone.  Management: Limit the buspirone dose to 2.5 mg daily and monitor patients for increased buspirone effects/toxicities if combined with strong CYP3A4 inhibitors. Dose adjustments of buspirone or a strong CYP3A4 inhibitor should be based on clinical assessment.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Busulfan: Itraconazole may increase the serum concentration of Busulfan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Butorphanol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Butorphanol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabazitaxel: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabazitaxel.  Management: Concurrent use of cabazitaxel with strong inhibitors of CYP3A4 should be avoided when possible. If such a combination must be used, consider a 25% reduction in the cabazitaxel dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabozantinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabozantinib.  Management: Avoid use of a strong CYP3A4 inhibitor with cabozantinib if possible. If combined, decrease cabozantinib capsules (Cometriq) by 40 mg from previous dose or decrease cabozantinib tablets (Cabometyx) by 20 mg from previous dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcifediol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Calcifediol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcitriol (Systemic): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Calcitriol (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabidiol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cannabidiol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabis: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cannabis. More specifically, tetrahydrocannabinol and cannabidiol serum concentrations may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Capivasertib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Capivasertib.  Management: Avoid concomitant use of capivasertib with strong CYP3A4 inhibitors when possible. If combined, reduce the capivasertib dose to 320 mg twice daily for 4 days, followed by 3 days off. Monitor patients closely for adverse reactions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Capmatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Capmatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cardiac Glycosides: Itraconazole may increase the serum concentration of Cardiac Glycosides.  Management: Measure cardiac glycoside serum concentrations before initiating treatment with itraconazole. Reduce cardiac glycoside concentrations by either reducing the dose by 30% to 50% or by modifying the dosing frequency.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cariprazine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Cariprazine. Specifically, concentrations of didesmethylcariprazine (DDCAR), the primary active metabolite of cariprazine, may increase. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cariprazine.  Management: Decrease cariprazine dose 50% (4.5 mg to 1.5 mg or 3 mg; 1.5 mg to 1.5 mg every other day) if starting a strong CYP3A4 inhibitor. If on a strong CYP3A4 inhibitor, start cariprazine at 1.5 mg day 1, 0 mg day 2, then 1.5 mg daily. May increase to 3 mg daily<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Celiprolol: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Celiprolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ceritinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ceritinib.  Management: Avoid this combination whenever possible. If combined, the ceritinib dose should be reduced by approximately one-third (to the nearest 150 mg). Resume the prior ceritinib dose after cessation of the strong CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ChlordiazePOXIDE: CYP3A4 Inhibitors (Strong) may increase the serum concentration of ChlordiazePOXIDE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ciclesonide (Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Ciclesonide (Oral Inhalation). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cilnidipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cilnidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cilostazol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cilostazol.  Management: Decrease the dose of cilostazol to 50 mg twice daily when combined with strong CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cinacalcet: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cinacalcet. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cisapride: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cisapride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clarithromycin: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Clarithromycin. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Clarithromycin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clindamycin (Systemic): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Clindamycin (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clobetasone: Itraconazole may increase the serum concentration of Clobetasone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ClonazePAM: CYP3A4 Inhibitors (Strong) may increase the serum concentration of ClonazePAM. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cobicistat: Itraconazole may increase the serum concentration of Cobicistat. Cobicistat may increase the serum concentration of Itraconazole.  Management: Limit itraconazole to a maximum adult dose of 200 mg/day in patients treated with the elvitegravir/cobicistat/emtricitabine/tenofovir combination products. Dosing recommendations for other cobicistat-containing products are not available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cobimetinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cobimetinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Codeine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Codeine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Colchicine: Itraconazole may increase the serum concentration of Colchicine.  Management: Colchicine is contraindicated during and for 2 weeks after itraconazole in patients with impaired renal or hepatic function. In those with normal renal and hepatic function, reduce colchicine dose as directed. See interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Conivaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Conivaptan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Copanlisib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Copanlisib.  Management: If concomitant use of copanlisib and strong CYP3A4 inhibitors cannot be avoided, reduce the copanlisib dose to 45 mg. Monitor patients for increased copanlisib effects/toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cortisone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cortisone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Crizotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Crizotinib.  Management: Avoid concomitant use of crizotinib and strong CYP3A4 inhibitors whenever possible. If combined use cannot be avoided, crizotinib dose reductions are required, which vary according to indication. See full interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloPHOSphamide: Itraconazole may enhance the adverse/toxic effect of CycloPHOSphamide. Specifically, serum creatinine and serum bilirubin may be increased. Itraconazole may increase the serum concentration of CycloPHOSphamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of CycloSPORINE (Systemic). Fluconazole and isavuconazonium considerations are addressed in separate monographs.  Management: Consider reducing cyclosporine doses by 50% to 80% during coadministration with ketoconazole, 50% with voriconazole or itraconazole, and 25% with posaconazole. Cyclosporine dose reductions may be required with other azoles.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease serum concentrations of the active metabolite(s) of Itraconazole. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Itraconazole.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease serum concentrations of the active metabolite(s) of Itraconazole. CYP3A4 Inducers (Strong) may decrease the serum concentration of Itraconazole.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Itraconazole.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Itraconazole.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cyproterone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cyproterone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabrafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dabrafenib.  Management: Consider alternatives to any strong CYP3A4 inhibitor for patients being treated with dabrafenib. If such a combination cannot be avoided, monitor closely for evidence of dabrafenib-related adverse effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daclatasvir: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Daclatasvir.  Management: Decrease the daclatasvir dose to 30 mg once daily if combined with a strong CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapoxetine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dapoxetine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Daridorexant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Darifenacin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Darifenacin.  Management: Limit the darifenacin dose to no more than 7.5 mg daily if combined with strong CYP3A4 inhibitors. Monitor patients for increased darifenacin toxicities (eg, dry mouth, constipation, headache, CNS effects) when these agents are combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Darolutamide: Inhibitors of CYP3A4 (Strong) and P-glycoprotein may increase the serum concentration of Darolutamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Darunavir: May increase the serum concentration of Itraconazole. Itraconazole may increase the serum concentration of Darunavir. Management: Limit the adult maximum itraconazole dose to 200 mg/day in patients receiving darunavir/ritonavir and monitor for increased itraconazole adverse effects during coadministration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dasatinib.  Management: This combination should be avoided if possible. If combined, decrease dasatinib dose from 140 mg to 40 mg, 100 mg to 20 mg, or 70 mg to 20 mg. For patients taking 60 mg or 40 mg daily, stop dasatinib until the CYP3A4 inhibitor is discontinued.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deflazacort: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Deflazacort.  Management: Administer one third of the recommended deflazacort dose when used together with a strong or moderate CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Delamanid: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Delamanid.  Management: Increase ECG monitoring frequency if delamanid is combined with strong CYP3A4 inhibitors due to the risk for QTc interval prolongation. Continue frequent ECG assessments throughout full delamanid treatment period.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexAMETHasone (Ophthalmic): CYP3A4 Inhibitors (Strong) may increase the serum concentration of DexAMETHasone (Ophthalmic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexAMETHasone (Systemic): CYP3A4 Inhibitors (Strong) may increase the serum concentration of DexAMETHasone (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DiazePAM: CYP3A4 Inhibitors (Strong) may increase the serum concentration of DiazePAM. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dichlorphenamide: Antifungal Agents (Azole Derivatives, Systemic) may enhance the hypokalemic effect of Dichlorphenamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Didanosine: May decrease the serum concentration of Itraconazole. Management: Administer itraconazole at least 2 hours prior to buffered didanosine. This interaction is not expected with enteric-coated didanosine capsules since they do not contain buffering agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dienogest: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dienogest. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DilTIAZem: CYP3A4 Inhibitors (Strong) may increase the serum concentration of DilTIAZem. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Disopyramide: Itraconazole may increase the serum concentration of Disopyramide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOCEtaxel: CYP3A4 Inhibitors (Strong) may increase the serum concentration of DOCEtaxel.  Management: Avoid the concomitant use of docetaxel and strong CYP3A4 inhibitors when possible. If combined use is unavoidable, consider a 50% docetaxel dose reduction and monitor for increased docetaxel toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dofetilide: Itraconazole may increase the serum concentration of Dofetilide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Domperidone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Domperidone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxazosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Doxazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxercalciferol: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Doxercalciferol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOXOrubicin (Conventional): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of DOXOrubicin (Conventional). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOXOrubicin (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of DOXOrubicin (Liposomal). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroNABinol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of DroNABinol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dronedarone: Itraconazole may increase the serum concentration of Dronedarone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dutasteride: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dutasteride. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Duvelisib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Duvelisib.  Management: Reduce the dose of duvelisib to 15 mg twice a day when used together with a strong CYP3A4 inhibitor. Monitor closely for evidence of altered response to treatment.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dydrogesterone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dydrogesterone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ebastine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Ebastine. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ebastine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Edoxaban: Itraconazole may increase the serum concentration of Edoxaban.  Management: In patients treated for DVT/PE, reduce the edoxaban dose to 30 mg daily when combined with itraconazole. No dose adjustment is recommended for patients treated for atrial fibrillation. Monitor for increased edoxaban toxicities (ie, bleeding) when combined<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efavirenz: May decrease serum concentrations of the active metabolite(s) of Itraconazole. Efavirenz may decrease the serum concentration of Itraconazole.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efonidipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Efonidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elacestrant: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Elacestrant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elagolix: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Elagolix.  Management: Use of the elagolix 200 mg twice daily dose with a strong CYP3A4 inhibitor for longer than 1 month is not recommended. Limit combined use of the elagolix 150 mg once daily dose with a strong CYP3A4 inhibitor to a maximum of 6 months.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elagolix, Estradiol, and Norethindrone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Elagolix, Estradiol, and Norethindrone. Elagolix, Estradiol, and Norethindrone may decrease the serum concentration of CYP3A4 Inhibitors (Strong). Specifically, concentrations of strong CYP3A4 inhibitors that are also CYP3A4 substrates may be decreased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elbasvir and Grazoprevir: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Elbasvir and Grazoprevir.  Management: Consider alternatives to this combination when possible. If combined, monitor for increased elbasvir/grazoprevir toxicities, including ALT elevations.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eletriptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eletriptan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elexacaftor, Tezacaftor, and Ivacaftor: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Elexacaftor, Tezacaftor, and Ivacaftor.  Management: Administer elexacaftor/tezacaftor/ivacaftor in the morning, twice a week, 3 to 4 days apart, with no evening doses of ivacaftor alone. Specific dosing varies by age and weight. See full monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eliglustat: Itraconazole may increase the serum concentration of Eliglustat.  Management: Reduce eliglustat dose to 84 mg daily in CYP2D6 EMs when used with itraconazole. Use of eliglustat is contraindicated during and for 2 weeks after itraconazole in CYP2D6 IMs, PMs, or in CYP2D6 EMs who are also taking strong or moderate CYP2D6 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Enasidenib: May decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Enfortumab Vedotin: Inhibitors of CYP3A4 (Strong) and P-glycoprotein may increase the serum concentration of Enfortumab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Entrectinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Entrectinib.  Management: Avoid strong CYP3A4 inhibitors if possible. If needed, reduce entrectinib dose to 50 mg on alternating days if starting dose 200 mg; to 50 mg/day if starting dose 300 mg or 400 mg; to 100 mg/day if starting dose 600 mg.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eplerenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eplerenone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erdafitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Erdafitinib.  Management: Avoid concomitant use of erdafitinib and strong CYP3A4 inhibitors when possible. If combined, monitor closely for erdafitinib adverse reactions and consider dose modifications accordingly.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erlotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Erlotinib.  Management: Avoid use of this combination when possible. When the combination must be used, monitor the patient closely for the development of erlotinib-associated adverse reactions, and if such severe reactions occur, reduce the erlotinib dose (in 50 mg decrements).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erythromycin (Systemic): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Erythromycin (Systemic).  Management: Consider alternatives to this combination when possible. If combined, monitor for increased erythromycin effects and toxicities, including QTc interval prolongation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Estazolam: Itraconazole may increase the serum concentration of Estazolam. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Estrogen Derivatives: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Estrogen Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eszopiclone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eszopiclone.  Management: Limit the eszopiclone dose to 2 mg daily when combined with strong CYP3A4 inhibitors and monitor for increased eszopiclone effects and toxicities (eg, somnolence, drowsiness, CNS depression).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etizolam: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Etizolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etoposide: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Etoposide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etoposide Phosphate: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Etoposide Phosphate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etravirine: Itraconazole may increase the serum concentration of Etravirine. Etravirine may decrease the serum concentration of Itraconazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Everolimus: Inhibitors of CYP3A4 (Strong) and P-glycoprotein may increase the serum concentration of Everolimus. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Evogliptin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Evogliptin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fedratinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fedratinib.  Management: Consider alternatives when possible. If used together, decrease fedratinib dose to 200 mg/day. After the inhibitor is stopped, increase fedratinib to 300 mg/day for the first 2 weeks and then to 400 mg/day as tolerated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Felodipine: Itraconazole may increase the serum concentration of Felodipine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">FentaNYL: CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.  Management: Consider fentanyl dose reductions when combined with a strong CYP3A4 inhibitor. Monitor for respiratory depression and sedation. Upon discontinuation of a CYP3A4 inhibitor, consider a fentanyl dose increase; monitor for signs and symptoms of withdrawal.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fesoterodine: Itraconazole may increase serum concentrations of the active metabolite(s) of Fesoterodine.  Management: Limit fesoterodine doses to 4 mg daily when combined with itraconazole. Use of fesoterodine with itraconazole, or for 2 weeks after itraconazole discontinuation, in patients with moderate to severe hepatic or renal impairment is contraindicated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Fexinidazole.  Management: Avoid use of fexinidazole and strong CYP3A4 inhibitors when possible. If combined, monitor for reduced fexinidazole efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Finerenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Finerenone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flibanserin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Flibanserin.  Management: Use of flibanserin with strong CYP3A4 inhibitors is contraindicated. If starting flibanserin, start 2 weeks after the last dose of the CYP3A4 inhibitor. If starting a CYP3A4 inhibitor, start 2 days after the last dose of flibanserin.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Flunitrazepam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluticasone (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Nasal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluticasone (Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Oral Inhalation).  Management: Consider alternatives to this combination if possible. Coadministration of fluticasone propionate and strong CYP3A4 inhibitors is not recommended. If combined, monitor patients for systemic corticosteroid adverse effects (eg, adrenal suppression).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluticasone (Topical): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosamprenavir: Itraconazole may increase serum concentrations of the active metabolite(s) of Fosamprenavir. Specifically, amprenavir concentrations may be increased. Fosamprenavir may increase the serum concentration of Itraconazole.  Management: Limit the adult maximum itraconazole dose to 200 mg/day with fosamprenavir/ritonavir. In patients receiving fosamprenavir without ritonavir, patients receiving greater than 400 mg/day itraconazole may also require dose reduction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosaprepitant: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fosaprepitant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fostamatinib: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fostamatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Futibatinib: Inhibitors of CYP3A4 (Strong) and P-glycoprotein may increase the serum concentration of Futibatinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Galantamine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Galantamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gefitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Gefitinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gepirone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Gepirone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gilteritinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Gilteritinib.  Management: Consider alternatives to the use of a strong CYP3A4 inhibitor with gilteritinib. If the combination cannot be avoided, monitor more closely for evidence of gilteritinib toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glasdegib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Glasdegib.  Management: Consider alternatives to this combination when possible. If the combination must be used, monitor closely for evidence of QT interval prolongation and other adverse reactions to glasdegib.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glecaprevir and Pibrentasvir: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Glecaprevir and Pibrentasvir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Grapefruit Juice: May decrease the serum concentration of Itraconazole. Grapefruit Juice may increase the serum concentration of Itraconazole.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">GuanFACINE: CYP3A4 Inhibitors (Strong) may increase the serum concentration of GuanFACINE.  Management: Reduce the extended-release guanfacine dose 50% when combined with a strong CYP3A4 inhibitor. Monitor for increased guanfacine toxicities when these agents are combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Halofantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Halofantrine.  Management: Consider alternatives to this combination whenever possible. If combined, monitor closely for halofantrine toxicities, including QTc interval prolongation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of Haloperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Haloperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Histamine H2 Receptor Antagonists: May increase the serum concentration of Itraconazole. Histamine H2 Receptor Antagonists may decrease the serum concentration of Itraconazole. Management: Administer Sporanox brand itraconazole at least 2 hours before or 2 hours after administration of any histamine H2 receptor antagonists (H2RAs). Exposure to Tolsura brand itraconazole may be increased by H2RAs; consider itraconazole dose reduction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hormonal Contraceptives: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Hormonal Contraceptives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HYDROcodone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of HYDROcodone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hydrocortisone (Systemic): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Hydrocortisone (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrexafungerp: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ibrexafungerp.  Management: Decrease the ibrexafungerp dose to 150 mg every 12 hours for 2 doses in patients receiving strong CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrutinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ibrutinib.  Management: Avoid concomitant use of ibrutinib and strong CYP3A4 inhibitors. If a strong CYP3A4 inhibitor must be used short-term (eg, anti-infectives for 7 days or less), interrupt ibrutinib therapy until the strong CYP3A4 inhibitor is discontinued.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Idelalisib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Idelalisib.  Management: Use alternative therapies that are not strong CYP3A4 inhibitors whenever possible. If unable to use alternative drugs, monitor patients more frequently for idelalisib toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ifosfamide: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iloperidone: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolites P88 and P95 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Iloperidone.  Management: Reduce iloperidone dose by half when administered with a strong CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Imatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Imatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Imidafenacin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Imidafenacin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indinavir: Itraconazole may increase the serum concentration of Indinavir. Indinavir may increase the serum concentration of Itraconazole.  Management: Reduce the indinavir dose to 600 mg every 8 hours when given with itraconazole. Monitor for increased systemic effects (including adverse/toxic effects) of itraconazole.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Infigratinib: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Infigratinib. CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Infigratinib. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Infigratinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inhibitors of the Proton Pump (PPIs and PCABs): May increase the serum concentration of Itraconazole. This specifically applies to the super bioavailable itraconazole products (eg, Tolsura brand). Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Itraconazole. This specifically applies to the non-super bioavailable itraconazole products (eg, Sporanox brand and its generics). Management: Exposure to Tolsura brand itraconazole may be increased by PPIs or PCABs ; consider itraconazole dose reduction. Exposure to Sporanox brand itraconazole may be decreased. Give Sporanox brand itraconazole at least 2 hrs before or 2 hrs after PPIs or PCABs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Irinotecan Products: Itraconazole may increase serum concentrations of the active metabolite(s) of Irinotecan Products. Specifically, serum concentrations of SN-38 may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isavuconazonium Sulfate: Itraconazole may increase the serum concentration of Isavuconazonium Sulfate. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isoniazid: May decrease the serum concentration of Itraconazole.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isradipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Isradipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Istradefylline: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Istradefylline.  Management: Limit the maximum istradefylline dose to 20 mg daily when combined with strong CYP3A4 inhibitors and monitor for increased istradefylline effects/toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivabradine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivabradine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivacaftor: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivacaftor.  Management: Ivacaftor dose reductions are required; consult full drug interaction monograph content for age- and weight-specific recommendations.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivosidenib: Itraconazole may increase the serum concentration of Ivosidenib. Ivosidenib may decrease the serum concentration of Itraconazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ixabepilone.  Management: Avoid use of ixabepilone and strong CYP3A4 inhibitors when possible. If combined, reduce the ixabepilone dose to 20 mg/m<sup>2</sup>. The previous ixabepilone dose can be resumed 1 week after discontinuation of the strong CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketamine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ketamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketoconazole (Systemic): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ketoconazole (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lacidipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lacidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lapatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lapatinib.  Management: Avoid use of lapatinib and strong CYP3A4 inhibitors when possible. If combined, a reduced lapatinib dose of 500 mg daily should be considered. The previous lapatinib dose can be resumed 1 week after discontinuation of the strong CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Larotrectinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Larotrectinib.  Management: Avoid use of strong CYP3A4 inhibitors with larotrectinib. If this combination cannot be avoided, reduce the larotrectinib dose by 50%. Increase to previous dose after stopping the inhibitor after a period of 3 to 5 times the inhibitor's half-life.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lefamulin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lefamulin.  Management: Avoid concomitant use of lefamulin tablets and strong inhibitors of CYP3A4.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lemborexant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leniolisib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Leniolisib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lercanidipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lercanidipine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Letermovir: Itraconazole may increase the serum concentration of Letermovir. Letermovir may decrease the serum concentration of Itraconazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leuprolide and Norethindrone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Leuprolide and Norethindrone. Specifically, concentrations of norethindrone may increase. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levamlodipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Levamlodipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levobupivacaine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Levobupivacaine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Levoketoconazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levomethadone: Itraconazole may increase the serum concentration of Levomethadone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levomilnacipran: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Levomilnacipran.  Management: The dose of levomilnacipran should not exceed 80 mg once daily when used with strong CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lidocaine (Systemic): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lidocaine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lomitapide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lomitapide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lonafarnib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lonafarnib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lopinavir: May increase the serum concentration of Itraconazole. Management: Itraconazole doses greater than 200 mg/day are not recommended in combination with lopinavir/ritonavir.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lorlatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lorlatinib.  Management: Avoid use of lorlatinib with strong CYP3A4 inhibitors. If the combination cannot be avoided, reduce the lorlatinib dose from 100 mg once daily to 75 mg once daily, or from 75 mg once daily to 50 mg once daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lovastatin: Itraconazole may increase the serum concentration of Lovastatin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumateperone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lumateperone.  Management: Limit the lumateperone dose to 10.5 mg once daily when used with a strong CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lurasidone: Itraconazole may increase the serum concentration of Lurasidone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lurbinectedin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lurbinectedin.  Management: Avoid concomitant use of lurbinectedin and strong CYP3A4 inhibitors. If coadministration with a strong CYP3A4 inhibitor cannot be avoided, reduce the lurbinectedin dose by 50%.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Macitentan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Macitentan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Manidipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Manidipine.  Management: Consider avoiding concomitant use of manidipine and strong CYP3A4 inhibitors. If combined, monitor closely for increased manidipine effects and toxicities. Manidipine dose reductions may be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maraviroc: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Maraviroc.  Management: Reduce maraviroc to 150mg twice/day in adult and pediatrics weighing 40kg or more. See full interaction monograph for dose adjustments in pediatrics weighing 10 to less than 40kg. Do not use if CrCl less than 30mL/min or in those weighing less than 10 kg.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mavacamten: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mavacamten. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mefloquine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mefloquine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Meloxicam: Itraconazole may decrease the serum concentration of Meloxicam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Meperidine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Meperidine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: Itraconazole may enhance the QTc-prolonging effect of Methadone. Itraconazole may increase the serum concentration of Methadone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">MethylPREDNISolone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midazolam: Itraconazole may increase the serum concentration of Midazolam.  Management: Oral midazolam is contraindicated with, and for 2 weeks after, itraconazole. Avoid use with nasal midazolam. Consider alternatives to use with other routes of midazolam (IV, IM) when possible. Consider use of lower midazolam doses  if combined.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midostaurin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Midostaurin.  Management: Seek alternatives to the concomitant use of midostaurin and strong CYP3A4 inhibitors if possible. If concomitant use cannot be avoided, monitor patients for increased risk of adverse reactions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">MiFEPRIStone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of MiFEPRIStone.  Management: For treatment of hyperglycemia in Cushing's syndrome, start mifepristone at 300 mg/day, may titrate to a maximum of 900 mg/day. If starting a strong CYP3A4 inhibitor and taking &gt; 300 mg/day mifepristone, decrease the mifepristone dose by 300 mg/day.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirodenafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mirodenafil.  Management: Consider using a lower dose of mirodenafil when used with strong CYP3A4 inhibitors. Monitor for increased mirodenafil effects/toxicities with the use of this combination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirtazapine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mirtazapine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirvetuximab Soravtansine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mirvetuximab Soravtansine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mitapivat: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mitapivat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mizolastine: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Mizolastine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mobocertinib: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Mobocertinib. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mobocertinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mometasone (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mometasone (Nasal). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mometasone (Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mometasone (Oral Inhalation). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mometasone (Topical): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mometasone (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Morphine (Systemic): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Morphine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadolol: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Nadolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naldemedine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Naldemedine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nalfurafine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nalfurafine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naloxegol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Naloxegol. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nelfinavir: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nelfinavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neratinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Neratinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nevirapine: May decrease the serum concentration of Itraconazole.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">NiCARdipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of NiCARdipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NIFEdipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of NIFEdipine.  Management: Consider alternatives to this combination when possible. If combined, initiate nifedipine at the lowest dose available and monitor patients closely for increased nifedipine effects and toxicities (eg, hypotension, edema).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nilotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nilotinib.  Management: Avoid if possible. If combination needed, decrease nilotinib to 300 mg once/day for patients with resistant or intolerant Ph+ CML or to 200 mg once/day for patients with newly diagnosed Ph+ CML in chronic phase.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nilvadipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nilvadipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NiMODipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of NiMODipine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nintedanib: Inhibitors of CYP3A4 (Strong) and P-glycoprotein may increase the serum concentration of Nintedanib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirmatrelvir and Ritonavir: Itraconazole may increase the serum concentration of Nirmatrelvir and Ritonavir. Nirmatrelvir and Ritonavir may increase the serum concentration of Itraconazole.  Management: Limit the adult maximum itraconazole dose to 200 mg/day in patients receiving nirmatrelvir/ritonavir.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirogacestat: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nirogacestat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nisoldipine: Itraconazole may increase the serum concentration of Nisoldipine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitrendipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nitrendipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Olaparib.  Management: Avoid use of strong CYP3A4 inhibitors with olaparib, if possible. If such concurrent use cannot be avoided, the dose of olaparib tablets should be reduced to 100 mg twice daily and the dose of olaparib capsules should be reduced to 150 mg twice daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oliceridine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Oliceridine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olmutinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Olmutinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omaveloxolone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Omaveloxolone.  Management: Avoid this combination if possible. If coadministration is required, decrease the omaveloxolone dose to 50 mg daily and monitor closely for adverse reactions. Discontinue coadministration if adverse reactions occur.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orelabrutinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Orelabrutinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Osilodrostat: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Osilodrostat.  Management: Reduce osilodrostat dose by 50% during coadministration with a strong CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ospemifene: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ospemifene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyBUTYnin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of OxyBUTYnin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of OxyCODONE. CYP3A4 Inhibitors (Strong) may increase the serum concentration of OxyCODONE. Serum concentrations of the active metabolite oxymorphone may also be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PACLitaxel (Conventional): CYP3A4 Inhibitors (Strong) may increase the serum concentration of PACLitaxel (Conventional). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PACLitaxel (Protein Bound): CYP3A4 Inhibitors (Strong) may increase the serum concentration of PACLitaxel (Protein Bound). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pacritinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pacritinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palbociclib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Palbociclib.  Management: Avoid concurrent use of strong CYP3A4 inhibitors with palbociclib when possible. If the use of a strong CYP3A4 inhibitor cannot be avoided, decrease the palbociclib dose to 75 mg/day.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palovarotene: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Palovarotene. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Panobinostat: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Panobinostat.  Management: Reduce the panobinostat dose to 10 mg when it must be used with a strong CYP3A4 inhibitor. Monitor patient response to therapy closely for evidence of more severe adverse effects related to panobinostat therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Parecoxib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Parecoxib. Specifically, serum concentrations of the active moiety valdecoxib may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paricalcitol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Paricalcitol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PAZOPanib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of PAZOPanib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pemigatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pemigatinib.  Management: If combined use cannot be avoided, reduce the pemigatinib dose from 13.5 mg daily to 9 mg daily, or from 9 mg daily to 4.5 mg daily. Resume prior pemigatinib dose after stopping the strong inhibitor once 3 half-lives of the inhibitor has passed.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pexidartinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pexidartinib.  Management: If combined use cannot be avoided, pexidartinib dose should be reduced. For the 125 mg capsules: reduce pexidartinib doses of 500 mg or 375 mg daily to 125 mg twice daily. Reduce pexidartinib 250 mg daily to 125 mg once daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimavanserin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pimavanserin.  Management: Decrease the pimavanserin dose to 10 mg daily when combined with strong CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: CYP3A4 Inhibitors (Strong) may decrease the metabolism of Pimecrolimus. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: Itraconazole may increase the serum concentration of Pimozide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piperaquine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Piperaquine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pirtobrutinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pirtobrutinib.  Management: Avoid concomitant use when possible. If combined, reduce the pirtobrutinib dose by 50 mg. If current dose is 50 mg, interrupt pirtobrutinib treatment during strong CYP3A4 inhibitor use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polatuzumab Vedotin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Polatuzumab Vedotin. Exposure to unconjugated MMAE, the cytotoxic small molecule component of polatuzumab vedotin, may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PONATinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of PONATinib.  Management: Avoid concomitant use if possible. If combined, reduce ponatinib dose as follows: If taking 45 mg, reduce to 30 mg; if taking 30 mg, reduce to 15 mg; if taking 15 mg, reduce to 10 mg. If taking 10 mg, avoid concomitant use with strong CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pralsetinib: Inhibitors of CYP3A4 (Strong) and P-glycoprotein may increase the serum concentration of Pralsetinib.  Management: Avoid concomitant use if possible. If combined, reduce the pralsetinib dose. If taking 400 mg or 300 mg once daily, reduce to 200 mg once daily. If taking 200 mg once daily, reduce to 100 mg once daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pravastatin: Itraconazole may increase the serum concentration of Pravastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prazepam: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Prazepam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Praziquantel: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Praziquantel. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PrednisoLONE (Systemic): CYP3A4 Inhibitors (Strong) may increase the serum concentration of PrednisoLONE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PredniSONE: CYP3A4 Inhibitors (Strong) may increase the serum concentration of PredniSONE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propafenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Propafenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QUEtiapine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of QUEtiapine.  Management: In quetiapine treated patients, reduce quetiapine to one-sixth of original dose after starting a strong CYP3A4 inhibitor. In those on strong CYP3A4 inhibitors, start quetiapine at lowest dose and up-titrate as needed.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNIDine: Itraconazole may increase the serum concentration of QuiNIDine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinidine (Non-Therapeutic): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Quinidine (Non-Therapeutic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNINE: CYP3A4 Inhibitors (Strong) may increase the serum concentration of QuiNINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quizartinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Quizartinib.  Management: If combination is necessary, reduce quizartinib dose as follows: from 53 mg daily to 26.5 mg daily; from 35.4 mg daily to 17.7 mg daily; from 26.5 mg daily to 17.7 mg daily. If taking 17.7 mg daily avoid quizartinib while on the strong CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Radotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Radotinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramelteon: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ramelteon. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ranolazine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Reboxetine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Reboxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Red Yeast Rice: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Red Yeast Rice. Specifically, concentrations of lovastatin and related compounds found in Red Yeast Rice may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Regorafenib: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Regorafenib. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Regorafenib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Relugolix: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Relugolix.  Management: Avoid coadministration of relugolix with oral P-gp inhibitors whenever possible. If combined, take relugolix at least 6 hours prior to the P-gp inhibitor and monitor patients more frequently for adverse reactions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Relugolix, Estradiol, and Norethindrone: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Relugolix, Estradiol, and Norethindrone.  Management: Avoid use of relugolix/estradiol/norethindrone with P-glycoprotein (P-gp) inhibitors. If concomitant use is unavoidable, relugolix/estradiol/norethindrone should be administered at least 6 hours before the P-gp inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Repaglinide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Repaglinide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Repotrectinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Repotrectinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Retapamulin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Retapamulin.  Management: The use of retapamulin with strong CYP3A4 inhibitors is not recommended in patients less than 2 years old. No action is required in other populations.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ribociclib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ribociclib.  Management: Avoid use of ribociclib with strong CYP3A4 inhibitors when possible; if combined use cannot be avoided, reduce ribociclib dose to 400 mg once daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rifabutin: Itraconazole may increase the serum concentration of Rifabutin. Rifabutin may decrease the serum concentration of Itraconazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAXIMin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of RifAXIMin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rilpivirine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Rilpivirine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rimegepant: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Rimegepant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Riociguat: Inhibitors of CYP3A4 (Strong) and P-glycoprotein may increase the serum concentration of Riociguat.  Management: Consider a riociguat starting dose of 0.5 mg 3 times a day when initiating riociguat in patients receiving strong CYP3A4 and P-gp inhibitors. Monitor for hypotension when these agents are combined and reduce the riociguat dose as needed.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ripretinib: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Ripretinib. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ripretinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RisperiDONE: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of RisperiDONE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritonavir: May increase the serum concentration of Itraconazole. Management: Limit the adult maximum itraconazole dose to 200 mg/day in patients receiving ritonavir.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivaroxaban: Inhibitors of CYP3A4 (Strong) and P-glycoprotein may increase the serum concentration of Rivaroxaban. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Roflumilast-Containing Products: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Roflumilast-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RomiDEPsin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of RomiDEPsin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rosuvastatin: Itraconazole may increase the serum concentration of Rosuvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rupatadine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Rupatadine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Systemic): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ruxolitinib (Systemic).  Management: This combination should be avoided under some circumstances; dose adjustments may be required in some circumstances and depend on the indication for ruxolitinib. See monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Saccharomyces boulardii: Antifungal Agents (Systemic and Oral [Non-Absorbable]) may diminish the therapeutic effect of Saccharomyces boulardii. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salmeterol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Salmeterol. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Saquinavir: Itraconazole may increase the serum concentration of Saquinavir. Saquinavir may increase the serum concentration of Itraconazole.  Management: Limit the adult maximum itraconazole dose to 200 mg/day in patients receiving saquinavir/ritonavir and monitor for saquinavir adverse effects, including cardiac arrhythmias.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">SAXagliptin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of SAXagliptin.  Management: Limit the saxagliptin dose to 2.5 mg daily when combined with strong CYP3A4 inhibitors. When using the saxagliptin combination products saxagliptin/dapagliflozin or saxagliptin/dapagliflozin/metformin, avoid use with strong CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selpercatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Selpercatinib.  Management: Avoid combination if possible. If use is necessary, reduce selpercatinib dose as follows: from 120 mg twice/day to 40 mg twice/day, or from 160 mg twice/day to 80 mg twice/day.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selumetinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Selumetinib.  Management: Avoid concomitant use when possible. If combined, selumetinib dose reductions are recommended and vary based on body surface area and selumetinib dose.  For details, see the full drug interaction monograph or selumetinib prescribing information.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Sertindole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sibutramine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Sibutramine. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Sibutramine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sildenafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Sildenafil.  Management: Use of sildenafil for pulmonary arterial hypertension (PAH) should be avoided with strong CYP3A4 inhibitors. When used for erectile dysfunction, consider using a lower starting dose of 25 mg and monitor patients for sildenafil toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Silodosin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simeprevir: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Simeprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simvastatin: Itraconazole may increase the serum concentration of Simvastatin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Conventional): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Sirolimus (Conventional).  Management: Avoid concurrent use of sirolimus with strong CYP3A4 inhibitors when possible and alternative agents with lesser interaction potential with sirolimus should be considered. Concomitant use of sirolimus and voriconazole or posaconazole is contraindicated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Conventional): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Sirolimus (Conventional).  Management: Avoid concurrent use of sirolimus with P-glycoprotein (P-gp) inhibitors when possible and alternative agents with lesser interaction potential with sirolimus should be considered. Monitor for increased sirolimus concentrations/toxicity if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Protein Bound): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Sirolimus (Protein Bound). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Topical): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Sirolimus (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solifenacin: Itraconazole may increase the serum concentration of Solifenacin.  Management: Limit adult solifenacin doses to 5 mg daily and limit pediatric doses to the starting dose. Do not use with itraconazole, or for 2 weeks after itraconazole discontinuation, in patients with moderate to severe hepatic impairment or severe renal impairment.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sonidegib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Sonidegib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sparsentan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Sparsentan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">SUFentanil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of SUFentanil.  Management: If a strong CYP3A4 inhibitor is initiated in a patient on sufentanil, consider a sufentanil dose reduction and monitor for increased sufentanil effects and toxicities (eg, respiratory depression).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">SUNItinib: Itraconazole may increase the serum concentration of SUNItinib.  Management: Avoid when possible. If combined, decrease sunitinib dose to a minimum of 37.5 mg daily when treating GIST or RCC. Decrease sunitinib dose to a minimum of 25 mg daily when treating PNET. Monitor patients for both reduced efficacy and increased toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Suvorexant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Itraconazole may increase the serum concentration of Tacrolimus (Systemic).  Management: Monitor tacrolimus concentrations closely during therapy with itraconazole; tacrolimus dose reductions will likely be required. The magnitude of this interaction may be greater in older patients or those with one or more CYP3A5*3 alleles.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tacrolimus (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tadalafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tadalafil.  Management: Avoid this combination in patients taking tadalafil for pulmonary arterial hypertension. In patients taking tadalafil for ED or BPH, max tadalafil dose is 2.5 mg if taking daily or 10 mg no more frequently than every 72 hours if used as needed.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talazoparib: Itraconazole may increase the serum concentration of Talazoparib.  Management: In breast cancer, if concurrent use cannot be avoided, reduce talazoparib dose to 0.75 mg once daily. In prostate cancer, monitor patients for increased adverse events.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tamsulosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tamsulosin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tasimelteon: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tasimelteon. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tazemetostat: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tazemetostat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tegaserod (Withdrawn from US Market): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Tegaserod (Withdrawn from US Market). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Temsirolimus: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Temsirolimus. Specifically, concentrations of sirolimus may be increased.  Management: Avoid concomitant use of temsirolimus and strong CYP3A4 inhibitors. If coadministration is unavoidable, decrease temsirolimus dose to 12.5 mg per week. Resume previous temsirolimus dose 1 week after discontinuation of the strong CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teniposide: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Teniposide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tenofovir Disoproxil Fumarate: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Tenofovir Disoproxil Fumarate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Terfenadine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Terfenadine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrahydrocannabinol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tetrahydrocannabinol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrahydrocannabinol and Cannabidiol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tetrahydrocannabinol and Cannabidiol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tezacaftor and Ivacaftor: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tezacaftor and Ivacaftor.  Management: If combined with strong CYP3A4 inhibitors, tezacaftor/ivacaftor should be administered in the morning, twice a week, approximately 3 to 4 days apart. Tezacaftor/ivacaftor dose depends on age and weight; see full Lexi-Interact monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiotepa: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Thiotepa. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Thiotepa.  Management: Avoid coadministration of thiotepa and strong CYP3A4 inhibitors. If concomitant use cannot be avoided, monitor for thiotepa adverse effects and decreased efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ticagrelor: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ticagrelor. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tipranavir: May increase the serum concentration of Itraconazole. Management: Adult itraconazole doses greater than 200 mg/day are not recommended in patients treated with tipranavir.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tisotumab Vedotin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tisotumab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tofacitinib.  Management: Tofacitinib dose reductions are recommended when combined with strong CYP3A4 inhibitors. Recommended dose adjustments vary by tofacitinib formulation and therapeutic indication. See full Lexi Interact monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tolterodine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolterodine.  Management: The maximum recommended dose of tolterodine is 2 mg per day (1 mg twice daily for immediate-release tablets or 2 mg daily for extended-release capsules) when used together with a strong CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tolvaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolvaptan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Toremifene: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Toremifene.  Management: Use of toremifene with strong CYP3A4 inhibitors should be avoided if possible. If coadministration is necessary, monitor for increased toremifene toxicities, including QTc interval prolongation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trabectedin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Trabectedin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraMADol: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of TraMADol. CYP3A4 Inhibitors (Strong) may increase the serum concentration of TraMADol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraZODone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of TraZODone.  Management: Consider the use of a lower trazodone dose and monitor for increased trazodone effects (eg, sedation, QTc prolongation) if combined with strong CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tretinoin (Systemic): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tretinoin (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triamcinolone (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Triamcinolone (Nasal). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triamcinolone (Ophthalmic): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Triamcinolone (Ophthalmic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triamcinolone (Systemic): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Triamcinolone (Systemic).  Management: Consider alternatives to this combination when possible. If combined, monitor for increased corticosteroid adverse effects during coadministration of triamcinolone and strong CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triamcinolone (Topical): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Triamcinolone (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triazolam: Itraconazole may increase the serum concentration of Triazolam. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ubrogepant: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ubrogepant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Udenafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Udenafil. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ulipristal: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ulipristal. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Upadacitinib.  Management: Upadacitinib dose adjustments are needed when combined with strong CYP3A4 inhibitors. Specific adjustments vary based on upadacitinib indication. See full interact monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valbenazine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Valbenazine. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Valbenazine.  Management: Reduce the valbenazine dose to 40 mg daily when combined with strong CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vamorolone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vamorolone.  Management: Reduce the vamorolone dose to 4 mg/kg daily, with a maximum dose of 200 mg daily for patients weighing over 50 kg, when combined with strong CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vardenafil: Itraconazole may increase the serum concentration of Vardenafil.  Management: Limit Levitra (vardenafil) dose to 5 mg per 24 hours with itraconazole 200 mg/day and 2.5 mg per 24 hours with itraconazole 400 mg/day. Avoid concomitant use of Staxyn (vardenafil) and itraconazole. Combined use is contraindicated outside of the US.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vemurafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vemurafenib.  Management: Avoid concurrent use of vemurafenib with strong CYP3A4 inhibitors when possible. If concomitant use is unavoidable, consider a vemurafenib dose reduction if clinically indicated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Venetoclax: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Venetoclax.  Management: Coadministration is contraindicated during venetoclax initiation and ramp-up in CLL/SLL patients. Reduced venetoclax doses are required during ramp-up for patients with AML, and all maintenance therapy. See full Lexi Interact monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verapamil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Verapamil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vilanterol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilanterol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vilazodone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone.  Management: Limit the maximum vilazodone dose to 20 mg daily in patients receiving strong CYP3A4 inhibitors. The original vilazodone dose can be resumed following discontinuation of the strong CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">VinBLAStine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of VinBLAStine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">VinCRIStine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of VinCRIStine.  Management: Seek alternatives to this combination when possible. If combined, monitor closely for vincristine toxicities (eg, neurotoxicity, gastrointestinal toxicity, myelosuppression).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">VinCRIStine (Liposomal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of VinCRIStine (Liposomal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vindesine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vindesine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vinflunine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Vinflunine. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vinflunine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vinorelbine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vinorelbine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Itraconazole may increase the serum concentration of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voclosporin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Voclosporin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vorapaxar: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vorapaxar. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voriconazole: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Voriconazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zanubrutinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zanubrutinib.  Management: Decrease the zanubrutinib dose to 80 mg once daily during coadministration with a strong CYP3A4 inhibitor. Further dose adjustments may be required for zanubrutinib toxicities, refer to prescribing information for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ziprasidone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ziprasidone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zolpidem. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zopiclone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zopiclone.  Management: If coadministered with strong CYP3A4 inhibitors, initiate zopiclone at 3.75 mg in adults, with a maximum dose of 5 mg. Monitor for zopiclone toxicity (eg, drowsiness, confusion, lethargy, ataxia, respiratory depression).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zuranolone.  Management: Reduce the zuranolone dose to 30 mg once daily when used concomitantly with a strong CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F185416"><span class="drugH1">Food Interactions</span>
<p style="text-indent:-2em;margin-left:2em;">Capsule (100 mg [Sporanox]): Absorption enhanced by food and possibly by gastric acidity. Non-diet cola drinks have been shown to increase the absorption of the capsules in patients with achlorhydria or those taking H<sub>2</sub>-receptor antagonists or other gastric acid suppressors. Grapefruit/grapefruit juice may decrease or increase itraconazole serum levels. Management: Take 100 mg capsules (Sporanox) immediately after meals. Keep grapefruit/grapefruit juice consumption consistent; monitor for altered effects with concomitant use.</p>
<p style="text-indent:-2em;margin-left:2em;">Capsule (65 mg [Tolsura]): Absorption increased when administered on an empty stomach; however, administration of Tolsura (2 x 65 mg capsule) with food results in exposure similar to those achieved when Sporanox (2 x 100 mg capsule) is administered with food. Management: Take 65 mg capsules (Tolsura) with food.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral solution: Food decreases the bioavailability and increases the time to peak concentration. Management: Take solution on an empty stomach 1 hour before or 2 hours after meals.</p></div>
<div class="block dic drugH1Div" id="F185406"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Capsule (100 mg [Sporanox] and 65 mg [Tolsura]): Take with food.</p>
<p style="text-indent:-2em;margin-left:2em;">Solution: Take without food, if possible.</p></div>
<div class="block rep_considerations drugH1Div" id="F49002493"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Use is contraindicated for the treatment of onychomycosis in patients planning to become pregnant. Due to the potential risk of congenital malformations, the manufacturer recommends that when used for the treatment of onychomycosis, patients who may become pregnant should use highly effective contraception during treatment and for 2 months following treatment. Therapy should begin on the second or third day following menses.</p></div>
<div class="block pri drugH1Div" id="F185405"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on available data, an increased risk of adverse pregnancy outcomes (major congenital malformations, or spontaneous abortion/stillbirth) has not been associated with maternal use of itraconazole in short courses; however, the risk of specific birth defects has not been adequately studied (Liu 2020). Congenital abnormalities (eg, skeletal, genitourinary tract, cardiovascular, and ophthalmic malformations; chromosomal abnormalities; multiple other malformations) have been reported during postmarketing surveillance; however, a causal relationship has not been established.</p>
<p style="text-indent:0em;margin-top:2em;">In general, all azole antifungals should be avoided in the first trimester. Itraconazole is specifically contraindicated for the treatment of onychomycosis during pregnancy. Although itraconazole is approved for the treatment of various fungal infections, when treatment of a systemic fungal infection is needed in pregnant patients, itraconazole should be avoided, especially during the first trimester in order to decrease the risk of potential teratogenic exposure (HHS [OI adult 2020]; IDSA [Chapman 2008]; IDSA [Galgiani 2016]; IDSA [Pappas 2016]; IDSA [Wheat 2007]).</p></div>
<div class="block mopp drugH1Div" id="F53567421"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Liver function in patients with preexisting hepatic dysfunction, and in all patients being treated for longer than 1 month; renal function; serum potassium; CBC. Monitor for peripheral neuropathy, prodromal signs of hepatitis, and signs and symptoms of heart failure. Serum concentration monitoring is routinely recommended, except for use for tinea capitis.</p></div>
<div class="block rerp drugH1Div" id="F53567301"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>The following targets are specific to measurement via high performance liquid chromatography (HPLC); the sum of the itraconazole and hydroxyitraconazole (active metabolite) concentrations should be used for interpretation and comparison to target values. Values obtained via bioassay are ~5 times (2 to 10 times) those obtained via HPLC; adjust targets based on which method is used for concentration determination (Ashbee 2014; Goodwin 2008; Hostetler 1993; IDSA [Pappas 2016]; Law 1994).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Timing of serum sampling:</b> Obtain trough concentration ~5 to 7 days after therapy is initiated or dose is adjusted (Ashbee 2014; Bradley 2023; Downes 2020); however, steady state may not be reached until at least 11 to 14 days of therapy in the absence of a loading dose (IDSA [Wheat 2007]; Leong 2019).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Recommended targets for trough concentrations:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Efficacy:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Prophylaxis: &gt;0.5 mg/L (Bradley 2023; Downes 2020; Leong 2019; <i>Red Book</i> [AAP 2021]).</p>
<p style="text-indent:-2em;margin-left:6em;">Treatment: ≥1 mg/L (IDSA [Chapman 2008]; IDSA [Kaufmann 2007]; IDSA [Pappas 2016]); IDSA [Wheat 2007]; <i>Red Book</i> [AAP 2021]; Stockmann 2014). For aspergillosis, may consider &gt;1.5 mg/L (IDSA [Patterson 2016]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Toxicity: </i>Typically maintain trough concentration &lt;5 mg/L to avoid toxicity (Bradley 2023; Gomez-Lopez 2020; HHS [OI pediatric] 2023; IDSA [Pappas 2016]; Stockmann 2014). Concentration associated with toxicity is not well established; risk of adverse reactions may increase as concentrations increase (Lestner 2009).</p></div>
<div class="block pha drugH1Div" id="F185383"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Interferes with cytochrome P450 activity, decreasing ergosterol synthesis (principal sterol in fungal cell membrane) and inhibiting cell membrane formation</p></div>
<div class="block phk drugH1Div" id="F185400"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption:</p>
<p style="text-indent:-2em;margin-left:4em;">Capsule: The 100 mg capsule (Sporanox) requires gastric acidity (absorption is increased when administered with food). The 65 mg capsule (Tolsura) has increased absorption when administered on an empty stomach; however, administration of Tolsura (2 x 65 mg capsule) with food results in exposures similar to those achieved when Sporanox (2 x 100 mg capsule) is administered with food.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral solution: Absorption increased on empty stomach.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Highly lipophilic and tissue concentrations are higher than plasma concentrations. The highest concentrations: adipose, omentum, endometrium, cervical and vaginal mucus, and skin/nails. Aqueous fluids (eg, CSF and urine) contain negligible amounts; distributes into bronchial exudate and sputum.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥7 months, Children, and Adolescents &lt;18 years: V<sub>d</sub>: Single dose: 18.5 ± 14.2 L/kg (Abdel-Rahman 2007).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: V<sub>d</sub>: &gt;700 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding, plasma: 99.8%; metabolite hydroxy-itraconazole: 99.6%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Extensively hepatic via CYP3A4 into &gt;30 metabolites including hydroxy-itraconazole (major metabolite); appears to have in vitro antifungal activity. Main metabolic pathway is oxidation; may undergo saturation metabolism with multiple dosing.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Variable; Oral solution: ~55%; increases by 30% under fasted conditions (oral solution); <b>Note:</b> Oral solution has a higher degree of bioavailability (149% ± 68%) relative to oral capsules; should not be interchanged.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥6 months and Children &lt;2 years: Oral solution: Itraconazole: 47.4 ± 55 hours; hydroxyitraconazole: 18 ± 18.1 hours (de Repentigny 1998).</p>
<p style="text-indent:-2em;margin-left:4em;">Children 2 to &lt;5 years: Oral solution: Itraconazole: 30.6 ± 25.3 hours; hydroxyitraconazole: 17.1 ± 14.5 hours (de Repentigny 1998).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥5 years: Oral solution: Itraconazole: 28.3 ± 9.6 hours; hydroxyitraconazole: 17.9 ± 8.7 hours (de Repentigny 1998).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: Oral: Single dose: 16 to 28 hours, Multiple doses: 34 to 42 hours; Cirrhosis (single dose): 37 hours (range: 20 to 54 hours).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: Capsules: 2 to 5 hours; Oral solution: 2.5 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (&lt;1% active drug, 35% as inactive metabolites); feces (54%; ~3% to 18% as unchanged drug).</p></div>
<div class="block phksp drugH1Div" id="F51193257"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Bioavailability is slightly reduced.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: C<sub>max</sub> was reduced by 47% and resulted in a twofold increase in half-life (capsules).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F185407"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Sporanox</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Micotenk | Sporanox</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Sporanox</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Sporanox</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Sporanox</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Orungal</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Sporanox</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Si mai ke | Sporanox</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Fungitral | Itraconazol | Itrol | Sporanox</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Sporanox</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Sempera</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Candinox</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Sporanox</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Sporanox</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Canadiol | Itraconazol genfarma | Sporanox</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Sporanox</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Sporanox</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Sporanox</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Assosept s | Bevonazole | Brovicton | Deratil | Fungospor | Isoflon | Itrabest | Itralfa | Itraviron | Itrazol | Mesmor | Micronazol | Mycodrox | Neo Candimyk | Soprazon | Sporanox</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Itracin | Itrazol | Sporanox</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Itrac 3</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Orungal | Sporanox</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Sporanox</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Sporanox</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Sporanox</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Afitra | Candiforce | Cosbeta ITZ | Funzi it | Ibitra | Intracan | It mac | Itapro | Itaspor | Itler 200 | Itrabond | Itracoe | Itragreat | Itratuf | Livafin o | Mycoclear</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Sporanox | Triasporin</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Itraconazole kobayashi kako | Itraconazole meiji | Itraconazole pfizer | Itraconet | Itrareel | Toracona</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Ailro | Altrazol | Artsol | Atzole | Bi tra | BR Itraconazole | Bt conazole | Btconazole | Celconazole | Ciconazole | Conatec | Daehwa itraconazole | Daewoong itraconazole | Ditra | Glotra | Hanall itraconazole | Hantrazol | Hitconazole | Hitrazol | Hitrazole | Huons itraconazole | Hutra | I conal | I tra | Icazol | Iconal | Iconazole | Iconox | Icozole | Inazol | Inazole | Inist Itraconazole | Iraco | Iracona | Iratzol | Irazole | Ironazol | Isnazol | Itacona | Itanazole | Itanox | Itazol | Itco | Itcogen | Itcona | Itconzole | Itcozen | Itcozole | Itnal | Itnazole | Itozole | Itra | Itracen | Itraco | Itracon | Itracona | Itraconazol daewon | Itracozole | Itral | Itranox | Itraone | Itraz | Itrix | J Cona | Jw itraconazole | Konitra | Leadnox | Nacozol | Newtracozole | Newtrazole | Oniconazole | Onikonazole | Pharma itraconazole | Reyon itraconazol | S cozole | Samsung itraconazole | Scolazole | Sconazole | Spocora | Sponazol | Sponex | Sporanox | Sporaone | Sporawon | Sporazin | Sporazole | Spotra | Stra | Temezole | Theitra | Tinaderm | Tracon | Tranox | Trazon | Tricona | Uronazole | Yootrazole | Zotra</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Orungal | Sempera</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Sporanox</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Orungal</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Fubizol | Iqcona</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Sporanox</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Trisporal</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Sporanox</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Sporanox</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Sporanox</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Onmel | Sporanox</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Sporanox</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Itrazol | Sporanox</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Irunin | Orungal</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Sporanox</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Sporanox</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Hitrazole | Sporanox</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Sporanox</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Sporanox</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Sporal</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Sporanox</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Itrazole | Sporanox</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Eszol | Orungal</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Itramir | Tarimagen</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Itraco | Sporanox | Sporozole</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-17517842">
<a name="17517842"></a>Abdel-Rahman SM, Jacobs RF, Massarella J, et al. Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents. <i>Antimicrob Agents Chemother</i>. 2007;51(8):2668-2673. doi:10.1128/AAC.00297-07<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/17517842/pubmed" id="17517842" target="_blank">17517842</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23496375">
<a name="23496375"></a>Agarwal R, Vishwanath G, Aggarwal AN, Garg M, Gupta D, Chakrabarti A. Itraconazole in chronic cavitary pulmonary aspergillosis: a randomised controlled trial and systematic review of literature. <i>Mycoses</i>. 2013;56(5):559-570. doi:10.1111/myc.12075<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/23496375/pubmed" id="23496375" target="_blank">23496375</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11403818">
<a name="11403818"></a>Ahmad SR, Singer SJ, Leissa BG. Congestive heart failure associated with itraconazole. <i>Lancet</i>. 2001;357(9270):1766-1767. doi:10.1016/S0140-6736(00)04891-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/11403818/pubmed" id="11403818" target="_blank">11403818</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Akuthota.1">
<a name="Akuthota.1"></a>Akuthota P, Weller PF. Treatment of allergic bronchopulmonary aspergillosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 24, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11444275">
<a name="11444275"></a>Alvarez-Fernández JG, Castaño-Suárez E, Cornejo-Navarro P, de la Fuente EG, Ortiz de Frutos FJ, Iglesias-Diez L. Photosensitivity induced by oral itraconazole. <i>J Eur Acad Dermatol Venereol</i>. 2000;14(6):501-503. doi:10.1046/j.1468-3083.2000.00164.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/11444275/pubmed" id="11444275" target="_blank">11444275</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25409999">
<a name="25409999"></a>Ameen M, Lear JT, Madan V, Mohd Mustapa MF, Richardson M. British Association of Dermatologists' guidelines for the management of onychomycosis 2014. <i>Br J Dermatol</i>. 2014;171(5):937-958. doi:10.1111/bjd.13358<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/25409999/pubmed" id="25409999" target="_blank">25409999</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. <i>Red Book: 2021-2024 Report of the Committee on Infectious Diseases</i>. 32nd ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24379304">
<a name="24379304"></a>Ashbee HR, Barnes RA, Johnson EM, Richardson MD, Gorton R, Hope WW. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. <i>J Antimicrob Chemother</i>. 2014;69(5):1162-1176. doi:10.1093/jac/dkt508<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/24379304/pubmed" id="24379304" target="_blank">24379304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31155770">
<a name="31155770"></a>Aslam S, Rotstein C; AST Infectious Disease Community of Practice. Candida infections in solid organ transplantation: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice (AST-IDCOP). <i>Clin Transplant</i>. 2019;33(9):e13623. doi:10.1111/ctr.13623<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/31155770/pubmed" id="31155770" target="_blank">31155770</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Baddley.1">
<a name="Baddley.1"></a>Baddley JW. Treatment of histoplasmosis in patients with HIV. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 7, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9661037">
<a name="9661037"></a>Barone JA, Moskovitz BL, Guarnieri J, et al. Enhanced bioavailability of itraconazole in hydroxypropyl-beta-cyclodextrin solution versus capsules in healthy volunteers. <i>Antimicrob Agents Chemother</i>. 1998;42(7):1862-1865. doi:10.1128/AAC.42.7.1862<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/9661037/pubmed" id="9661037" target="_blank">9661037</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21685202">
<a name="21685202"></a>Baxter CG, Marshall A, Roberts M, Felton TW, Denning DW. Peripheral neuropathy in patients on long-term triazole antifungal therapy. <i>J Antimicrob Chemother</i>. 2011;66(9):2136-2139. doi:10.1093/jac/dkr233<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/21685202/pubmed" id="21685202" target="_blank">21685202</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31982514">
<a name="31982514"></a>Beck KR, Telisman L, van Koppen CJ, Thompson GR 3rd, Odermatt A. Molecular mechanisms of posaconazole- and itraconazole-induced pseudohyperaldosteronism and assessment of other systemically used azole antifungals. <i>J Steroid Biochem Mol Biol</i>. 2020;199:105605. doi:10.1016/j.jsbmb.2020.105605<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/31982514/pubmed" id="31982514" target="_blank">31982514</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18779889">
<a name="18779889"></a>Benedix F, Schilling M, Schaller M, Röcken M, Biedermann T. A young woman with recurrent vesicles on the lower lip: fixed drug eruption mimicking herpes simplex. <i>Acta Derm Venereol</i>. 2008;88(5):491-494. doi:10.2340/00015555-0519<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/18779889/pubmed" id="18779889" target="_blank">18779889</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31093949">
<a name="31093949"></a>Benitez LL, Carver PL. Adverse effects associated with long-term administration of azole antifungal agents. <i>Drugs</i>. 2019;79(8):833-853. doi:10.1007/s40265-019-01127-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/31093949/pubmed" id="31093949" target="_blank">31093949</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27430151">
<a name="27430151"></a>Benjamin Lash D, Jolliff J, Munoz A, Heidari A. Cross-reactivity between voriconazole, fluconazole and itraconazole. <i>J Clin Pharm Ther</i>. 2016;41(5):566-567. doi:10.1111/jcpt.12417<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/27430151/pubmed" id="27430151" target="_blank">27430151</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29441476">
<a name="29441476"></a>Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. <i>Clin Pharmacokinet.</i> 2018;57(9):1107-1121. doi:10.1007/s40262-018-0636-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/29441476/pubmed" id="29441476" target="_blank">29441476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19453785">
<a name="19453785"></a>Binder B, Richtig E, Weger W, et al. Tinea Capitis in Early Infancy Treated With Itraconazole: A Pilot Study. <i>J Eur Acad Dermatol Venereol.</i> 2009;23(10):1161-1163.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/19453785/pubmed" id="19453785" target="_blank">19453785</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8064084">
<a name="8064084"></a>Bittleman DB, Stapleton J, Casale TB. Report of successful desensitization to itraconazole. <i>J Allergy Clin Immunol</i>. 1994;94(2 Pt 1):270-271. doi:10.1016/0091-6749(94)90054-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/8064084/pubmed" id="8064084" target="_blank">8064084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Blair.1">
<a name="Blair.1"></a>Blair JE, Ampel NM. Primary pulmonary coccidioidal infection. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 29, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30558872">
<a name="30558872"></a>Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. <i>Lancet</i>. 2019;393(10167):183-198. doi:10.1016/S0140-6736(18)32218-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/30558872/pubmed" id="30558872" target="_blank">30558872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2847635">
<a name="2847635"></a>Boelaert J, Schurgers M, Matthys E, et al. Itraconazole pharmacokinetics in patients with renal dysfunction. <i>Antimicrob Agents Chemother.</i> 1988;32(10):1595-1597. doi:10.1128/AAC.32.10.1595<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/2847635/pubmed" id="2847635" target="_blank">2847635</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9919895">
<a name="9919895"></a>Boonk W, de Geer D, de Kreek E, Remme J, van Huystee B. Itraconazole in the treatment of tinea corporis and tinea cruris: comparison of two treatment schedules. <i>Mycoses</i>. 1998;41(11-12):509-514. doi:10.1111/j.1439-0507.1998.tb00714.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/9919895/pubmed" id="9919895" target="_blank">9919895</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24577007">
<a name="24577007"></a>Borges SR, Silva GM, Chambela Mda C, et al. Itraconazole vs. trimethoprim-sulfamethoxazole: a comparative cohort study of 200 patients with paracoccidioidomycosis. <i>Med Mycol</i>. 2014;52(3):303-310. doi:10.1093/mmy/myt012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/24577007/pubmed" id="24577007" target="_blank">24577007</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bradley.1">
<a name="Bradley.1"></a>Bradley JS, Nelson JD, Kimberlin DK, et al, eds. <i>Nelson's Pediatric Antimicrobial Therapy</i>. 29th ed. American Academy of Pediatrics; 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bradsher.1">
<a name="Bradsher.1"></a>Bradsher RW. Treatment of blastomycosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 12, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34144953">
<a name="34144953"></a>Brandi SL, Feltoft CL, Serup J, Eldrup E. Pseudohyperaldosteroism during itraconazole treatment: a hitherto neglected clinically significant side effect. <i>BMJ Case Rep</i>. 2021;14(6):e243191. doi:10.1136/bcr-2021-243191<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/34144953/pubmed" id="34144953" target="_blank">34144953</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26120552">
<a name="26120552"></a>Brockow K, Przybilla B, Aberer W, et al. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM). <i>Allergo J Int</i>. 2015;24(3):94-105. doi:10.1007/s40629-015-0052-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/26120552/pubmed" id="26120552" target="_blank">26120552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19645709">
<a name="19645709"></a>Cadena J, Levine DJ, Angel LF, et al. Antifungal prophylaxis with voriconazole or itraconazole in lung transplant recipients: hepatotoxicity and effectiveness. <i>Am J Transplant</i>. 2009;9(9):2085-2091. doi:10.1111/j.1600-6143.2009.02734.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/19645709/pubmed" id="19645709" target="_blank">19645709</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11550120">
<a name="11550120"></a>Caillot D, Bassaris H, McGeer A, et al. Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. <i>Clin Infect Dis</i>. 2001;33(8):e83-90. doi:10.1086/323020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/11550120/pubmed" id="11550120" target="_blank">11550120</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20055840">
<a name="20055840"></a>Cançado GG, Fujiwara RT, Freitas PA, Correa-Oliveira R, Bethony JM. Acute generalized exanthematous pustulosis induced by itraconazole: an immunological approach. <i>Clin Exp Dermatol</i>. 2009;34(8):e709-e711. doi:10.1111/j.1365-2230.2009.03440.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/20055840/pubmed" id="20055840" target="_blank">20055840</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18462107">
<a name="18462107"></a>Chapman SW, Dismukes WE, Proia LA, et al; Infectious Diseases Society of America (IDSA). Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. <i>Clin Infect Dis.</i> 2008;46(12):1801-1812.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/18462107/pubmed" id="18462107" target="_blank">18462107</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19261964">
<a name="19261964"></a>Chen J, Song X, Yang P, Wang J. Appearance of anaphylactic shock after long-term intravenous itraconazole treatment. <i>Ann Pharmacother</i>. 2009;43(3):537-541. doi:10.1345/aph.1L343<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/19261964/pubmed" id="19261964" target="_blank">19261964</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7829423">
<a name="7829423"></a>Coronel B, Persat F, Dorez D, Moskovtchenko JF, Peins MA, Mercatello A. Itraconazole concentrations during continuous haemodiafiltration.<i> J Antimicrob Chemother</i>. 1994;34(3):448-449. doi:10.1093/jac/34.3.448<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/7829423/pubmed" id="7829423" target="_blank">7829423</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32959476">
<a name="32959476"></a>Das A, Sil A, Mohanty S. Itraconazole-induced Stevens-Johnson syndrome and toxic epidermal necrolysis overlap: Report of a rare incident. <i>Dermatol Ther</i>. 2020;33(6):e14311. doi:10.1111/dth.14311<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/32959476/pubmed" id="32959476" target="_blank">32959476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21628477">
<a name="21628477"></a>de Lima Barros MB, Schubach AO, de Vasconcellos Carvalhaes de Oliveira R, Martins EB, Teixeira JL, Wanke B. Treatment of cutaneous sporotrichosis with itraconazole--study of 645 patients. <i>Clin Infect Dis</i>. 2011;52(12):e200-206. doi:10.1093/cid/cir245<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/21628477/pubmed" id="21628477" target="_blank">21628477</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10384922">
<a name="10384922"></a>Degreef H, del Palacio A, Mygind S, Ginter G, Pinto Soares A, Zuluaga de Cadena A. Randomized double-blind comparison of short-term itraconazole and terbinafine therapy for toenail onychomycosis. <i>Acta Derm Venereol</i>. 1999;79(3):221-223. doi:10.1080/000155599750011020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/10384922/pubmed" id="10384922" target="_blank">10384922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8059779">
<a name="8059779"></a>Denning DW, Lee JY, Hostetler JS, et al. NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis. <i>Am J Med.</i> 1994;97(2):135-144.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/8059779/pubmed" id="8059779" target="_blank">8059779</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9527794">
<a name="9527794"></a>de Repentigny L, Ratelle J, Leclerc JM, et al. Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children. <i>Antimicrob Agents Chemother</i>. 1998;42(2):404-408. doi:10.1128/AAC.42.2.404<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/9527794/pubmed" id="9527794" target="_blank">9527794</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1332471">
<a name="1332471"></a>Dismukes WE, Bradsher RW Jr, Cloud GC, et al; NIAID Mycoses Study Group. Itraconazole therapy for blastomycosis and histoplasmosis. <i>Am J Med</i>. 1992;93(5):489-497. doi:10.1016/0002-9343(92)90575-v<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/1332471/pubmed" id="1332471" target="_blank">1332471</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9042060">
<a name="9042060"></a>Douglas R, Spelman D, Czarny D, O'Hehir R. Desensitization to itraconazole. <i>J Allergy Clin Immunol</i>. 1997;99(2):269. doi:10.1016/s0091-6749(97)70111-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/9042060/pubmed" id="9042060" target="_blank">9042060</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31974859">
<a name="31974859"></a>Downes KJ, Fisher BT, Zane NR. Administration and dosing of systemic antifungal agents in pediatric patients. <i>Paediatr Drugs</i>. 2020;22(2):165-188. doi:10.1007/s40272-020-00379-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/31974859/pubmed" id="31974859" target="_blank">31974859</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8642095">
<a name="8642095"></a>Drake LA, Dinehart SM, Farmer ER, et al; Guidelines/Outcomes Committee. American Academy of Dermatology. Guidelines of care for superficial mycotic infections of the skin: Pityriasis (tinea) versicolor. <i>J Am Acad Dermatol.</i> 1996;34(2 Pt 1):287-289.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/8642095/pubmed" id="8642095" target="_blank">8642095</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27028785">
<a name="27028785"></a>Eloranta K, Karakorpi H, Jeskanen L, Kluger N. Photo-distributed Stevens-Johnson syndrome associated with oral itraconazole. <i>Int J Dermatol</i>. 2016;55(9):e508-10. doi:10.1111/ijd.13278<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/27028785/pubmed" id="27028785" target="_blank">27028785</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-DOR.1">
<a name="DOR.1"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30076688">
<a name="30076688"></a>Ferguson-Paul K, Park C, Childress S, Arnold S, Ault B, Bagga B. Disseminated histoplasmosis in pediatric kidney transplant recipients-a report of six cases and review of the literature. <i>Pediatr Transplant</i>. 2018;22(7):e13274. doi:10.1111/petr.13274<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/30076688/pubmed" id="30076688" target="_blank">30076688</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fishman.1">
<a name="Fishman.1"></a>Fishman JA, Alexander BD. Prophylaxis of infections in solid organ transplantation. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 23, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17631506">
<a name="17631506"></a>Freeman J, Heshmati A, Holland D, Ticehurst R, Lang S. Marked increase in steady-state serum levels achieved with itraconazole oral solution compared with capsule formulation. <i>J Antimicrob Chemother</i>. 2007;60(4):908-909. doi:10.1093/jac/dkm272<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/17631506/pubmed" id="17631506" target="_blank">17631506</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25234064">
<a name="25234064"></a>Fuller LC, Barton RC, Mohd Mustapa MF, Proudfoot LE, Punjabi SP, Higgins EM. British Association of Dermatologists' guidelines for the management of tinea capitis 2014. <i>Br J Dermatol</i>. 2014;171(3):454-463.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/25234064/pubmed" id="25234064" target="_blank">25234064</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18591345">
<a name="18591345"></a>Fung SL, Chau CH, Yew WW. Cardiovascular adverse effects during itraconazole therapy. <i>Eur Respir J</i>. 2008;32(1):240. doi:10.1183/09031936.00021208<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/18591345/pubmed" id="18591345" target="_blank">18591345</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27470238">
<a name="27470238"></a>Galgiani JN, Ampel NM, Blair JE, et al. 2016 Infectious Diseases Society of America (IDSA) clinical practice guideline for the treatment of coccidioidomycosis. <i>Clin Infect Dis</i>. 2016;63(6):e112-e146. doi:10.1093/cid/ciw360<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/27470238/pubmed" id="27470238" target="_blank">27470238</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11074900">
<a name="11074900"></a>Galgiani JN, Catanzaro A, Cloud GA, et al. Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis. A randomized, double-blind trial. Mycoses Study Group. <i>Ann Intern Med</i>. 2000;133(9):676-686. doi:10.7326/0003-4819-133-9-200011070-00009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/11074900/pubmed" id="11074900" target="_blank">11074900</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12802027">
<a name="12802027"></a>Gallin JI, Alling DW, Malech HL, et al. Itraconazole to prevent fungal infections in chronic granulomatous disease. <i>N Engl J Med</i>. 2003;348(24):2416-2422. doi:10.1056/NEJMoa021931<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/12802027/pubmed" id="12802027" target="_blank">12802027</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15283801">
<a name="15283801"></a>Ginter-Hanselmayer G, Smolle J, Gupta A. Itraconazole in the treatment of tinea capitis caused by Microsporum canis: experience in a large cohort. <i>Pediatr Dermatol</i>. 2004;21(4):499-502.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/15283801/pubmed" id="15283801" target="_blank">15283801</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16339606">
<a name="16339606"></a>Glasmacher A, Cornely O, Ullmann AJ, et al; Itraconazole Research Group of Germany. An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. <i>J Antimicrob Chemother</i>. 2006;57(2):317-325. doi:10.1093/jac/dki440<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/16339606/pubmed" id="16339606" target="_blank">16339606</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Goldstein.1">
<a name="Goldstein.1"></a>Goldstein AO, Bhatia N. Onychomycosis: management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 15, 2022a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Goldstein.2020a">
<a name="Goldstein.2020a"></a>Goldstein AO, Goldstein BG. Dermatophyte (tinea) infections. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 12, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Goldstein.2020b">
<a name="Goldstein.2020b"></a>Goldstein BG, Goldstein AO. Tinea versicolor (pityriasis versicolor). Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 12, 2022b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32535150">
<a name="32535150"></a>Gómez-López A. Antifungal therapeutic drug monitoring: focus on drugs without a clear recommendation. <i>Clin Microbiol Infect</i>. 2020;26(11):1481-1487. doi:10.1016/j.cmi.2020.05.037<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/32535150/pubmed" id="32535150" target="_blank">32535150</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17999982">
<a name="17999982"></a>Goodwin ML, Drew RH. Antifungal serum concentration monitoring: an update. <i>J Antimicrob Chemother</i>. 2008;61(1):17-25. doi:10.1093/jac/dkm389<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/17999982/pubmed" id="17999982" target="_blank">17999982</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10721851">
<a name="10721851"></a>Goto Y, Kono T, Teramae K, Ishii M. Itraconazole-induced drug eruption confirmed by challenge test. <i>Acta Derm Venereol</i>. 2000;80(1):72. doi:10.1080/000155500750012694<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/10721851/pubmed" id="10721851" target="_blank">10721851</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12121932">
<a name="12121932"></a>Groll AH, Wood L, Roden M, et al. Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis. <i>Antimicrob Agents Chemother</i>. 2002;46(8):2554-2563. doi:10.1128/AAC.46.8.2554-2563.2002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/12121932/pubmed" id="12121932" target="_blank">12121932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31085618">
<a name="31085618"></a>Guliani A, Chauhan A. Fixed drug eruption due to itraconazole: a rare occurence. <i>Postgrad Med J</i>. 2019;95(1124):340-341. doi:10.1136/postgradmedj-2019-136680<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/31085618/pubmed" id="31085618" target="_blank">31085618</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1737692">
<a name="1737692"></a>Gupta AK, Adam P, Dlova N, et al. Therapeutic options for the treatment of tinea capitis caused by <i>Trichophyton</i> species: griseofulvin versus the new oral antifungal agents, terbinafine, itraconazole, and fluconazole. <i>Pediatr Dermatol</i>. 2001a;18(5):433-438.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/1737692/pubmed" id="1737692" target="_blank">1737692</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9292075">
<a name="9292075"></a>Gupta AK, Alexis ME, Raboobee N, et al. Itraconazole pulse therapy is effective in the treatment of tinea capitis in children: an open multicentre study. <i>Br J Dermatol</i>. 1997;137(2):251-254.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/9292075/pubmed" id="9292075" target="_blank">9292075</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32897584">
<a name="32897584"></a>Gupta AK, Bamimore MA, Renaud HJ, Shear NH, Piguet V. A network meta-analysis on the efficacy and safety of monotherapies for tinea capitis, and an assessment of evidence quality. <i>Pediatr Dermatol</i>. 2020;37(6):1014-1022. doi:10.1111/pde.14353<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/32897584/pubmed" id="32897584" target="_blank">32897584</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12956196">
<a name="12956196"></a>Gupta AK, Batra R, Bluhm R, Faergemann J. Pityriasis versicolor. <i>Dermatol Clin</i>. 2003;21(3):413-429. doi:10.1016/s0733-8635(03)00039-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/12956196/pubmed" id="12956196" target="_blank">12956196</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18478357">
<a name="18478357"></a>Gupta AK, Cooper EA. Update in antifungal therapy of dermatophytosis. <i>Mycopathologia</i>. 2008;166(5-6):353-367. doi:10.1007/s11046-008-9109-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/18478357/pubmed" id="18478357" target="_blank">18478357</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gupta.1">
<a name="Gupta.1"></a>Gupta AK, Ginter G. Itraconazole is effective in the treatment of tinea capitis caused by <i>Microsporum canis</i>. <i>Pediatr Dermatol</i>. 2001b;18(6):519-522.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9861736">
<a name="9861736"></a>Gupta AK, Groen K, Woestenborghs R, De Doncker P. Itraconazole pulse therapy is effective in the treatment of Majocchi's granuloma: a clinical and pharmacokinetic evaluation and implications for possible effectiveness in tinea capitis. <i>Clin Exp Dermatol</i>. 1998;23(3):103-108. doi:10.1046/j.1365-2230.1998.00319.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/9861736/pubmed" id="9861736" target="_blank">9861736</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9704832">
<a name="9704832"></a>Gupta AK, Hofstader SL, Summerbell RC, et al. Treatment of tinea capitis with itraconazole capsule pulse therapy. <i>J Am Acad Dermatol</i>. 1998b;39(2, pt 1):216-219. doi:10.1016/s0190-9622(98)70078-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/9704832/pubmed" id="9704832" target="_blank">9704832</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24636433">
<a name="24636433"></a>Gupta AK, Lane D, Paquet M. Systematic review of systemic treatments for tinea versicolor and evidence-based dosing regimen recommendations. <i>J Cutan Med Surg</i>. 2014;18(2):79-90. doi:10.2310/7750.2013.13062<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/24636433/pubmed" id="24636433" target="_blank">24636433</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9764158">
<a name="9764158"></a>Gupta AK, Solomon RS, Adam P. Itraconazole oral solution for the treatment of tinea capitis. <i>Br J Dermatol</i>. 1998a;139(1):104-106. doi:10.1046/j.1365-2133.1998.02323.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/9764158/pubmed" id="9764158" target="_blank">9764158</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18280361">
<a name="18280361"></a>Gupta R, Thami GP. Fixed drug eruption caused by itraconazole: Reactivity and cross reactivity. <i>J Am Acad Dermatol</i>. 2008;58(3):521-522. doi:10.1016/j.jaad.2006.06.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/18280361/pubmed" id="18280361" target="_blank">18280361</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24556907">
<a name="24556907"></a>Hald M, Arendrup MC, Svejgaard EL, Lindskov R, Foged EK, Saunte DM; Danish Society of Dermatology. Evidence-based Danish guidelines for the treatment of Malassezia-related skin diseases. <i>Acta Derm Venereol</i>. 2015;95(1):12-19. doi:10.2340/00015555-1825<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/24556907/pubmed" id="24556907" target="_blank">24556907</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19730409">
<a name="19730409"></a>HHS, Centers for Disease Control and Prevention (CDC). Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children. November 2013. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4169043/" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4169043/</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/19730409/pubmed" id="19730409" target="_blank">19730409</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32594647">
<a name="32594647"></a>Hassanandani T, Panda M, Agarwal A, Das A. Rising trends of symmetrical drug related intertriginous and flexural exanthem due to Itraconazole in patients with superficial dermatophytosis: A case series of 12 patients from eastern part of India. <i>Dermatol Ther</i>. 2020;33(6):e13911. doi:10.1111/dth.13911<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/32594647/pubmed" id="32594647" target="_blank">32594647</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23677844">
<a name="23677844"></a>Hauben M, Hung EY. A quantitative analysis of the spontaneous reporting of congestive heart failure-related adverse events with systemic anti-fungal drugs. <i>J Clin Pharmacol</i>. 2013;53(7):762-772. doi:10.1002/jcph.84<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/23677844/pubmed" id="23677844" target="_blank">23677844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29385285">
<a name="29385285"></a>Hoffmann WJ, McHardy I, Thompson GR 3rd. Itraconazole induced hypertension and hypokalemia: Mechanistic evaluation. <i>Mycoses</i>. 2018;61(5):337-339. doi:10.1111/myc.12749<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/29385285/pubmed" id="29385285" target="_blank">29385285</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19884875">
<a name="19884875"></a>Homans JD, Spencer L. Itraconazole treatment of nonmeningeal coccidioidomycosis in children: two case reports and review of the literature. <i>Pediatr Infect Dis J</i>. 2010;29(1):65-67.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/19884875/pubmed" id="19884875" target="_blank">19884875</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8257148">
<a name="8257148"></a>Hostetler JS, Heykants J, Clemons KV, Woestenborghs R, Hanson LH, Stevens DA. Discrepancies in bioassay and chromatography determinations explained by metabolism of itraconazole to hydroxyitraconazole: studies of interpatient variations in concentrations. <i>Antimicrob Agents Chemother</i>. 1993;37(10):2224-2227. doi:10.1128/AAC.37.10.2224<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/8257148/pubmed" id="8257148" target="_blank">8257148</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30900296">
<a name="30900296"></a>Husain S, Camargo JF. Invasive aspergillosis in solid-organ transplant recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice (AST-IDCOP). <i>Clin Transplant</i>. 2019;33(9):e13544. doi:10.1111/ctr.13544<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/30900296/pubmed" id="30900296" target="_blank">30900296</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20575631">
<a name="20575631"></a>Iwamoto T, Ishibashi M, Fujieda A, Masuya M, Katayama N, Okuda M. Drug interaction between itraconazole and bortezomib: exacerbation of peripheral neuropathy and thrombocytopenia induced by bortezomib. <i>Pharmacotherapy</i>. 2010;30(7):661-665. doi:10.1592/phco.30.7.661<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/20575631/pubmed" id="20575631" target="_blank">20575631</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Jackson.2021">
<a name="Jackson.2021"></a>Jackson JD. Infectious folliculitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 14, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Jaroszewski.1">
<a name="Jaroszewski.1"></a>Jaroszewski D, Blair JE, Ampel NM. Management of pulmonary sequelae and complications of coccidioidomycosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 24, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32756879">
<a name="32756879"></a>Johnson MD, Lewis RE, Dodds Ashley ES, et al. Core recommendations for antifungal stewardship: a statement of the Mycoses Study Group Education and Research Consortium. <i>J Infect Dis</i>. 2020;222(suppl 3):S175-S198. doi:10.1093/infdis/jiaa394<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/32756879/pubmed" id="32756879" target="_blank">32756879</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20609140">
<a name="20609140"></a>Kakourou T, Uksal U, European Society for Pediatric Dermatology. Guidelines for the management of tinea capitis in children. <i>Pediatr Dermatol</i>. 2010;27(3):226-228.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/20609140/pubmed" id="20609140" target="_blank">20609140</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32767394">
<a name="32767394"></a>Kalita BJ, Das S, Dutta B. Itraconazole-induced symmetrical drug-related intertriginous and flexural exanthema (SDRIFE): a rare occurrence. <i>Int J Dermatol</i>. 2020;59(11):e419-e421. doi:10.1111/ijd.15049<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/32767394/pubmed" id="32767394" target="_blank">32767394</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23750489">
<a name="23750489"></a>Kao WY, Su CW, Huang YS, et al. Risk of oral antifungal agent-induced liver injury in Taiwanese. <i>Br J Clin Pharmacol</i>. 2014;77(1):180-189. doi:10.1111/bcp.12178<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/23750489/pubmed" id="23750489" target="_blank">23750489</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21477327">
<a name="21477327"></a>Karadi RL, Gow D, Kellett M, Denning DW, O'Driscoll RB. Itraconazole associated quadriparesis and edema: a case report. <i>J Med Case Rep</i>. 2011;5:140. doi:10.1186/1752-1947-5-140<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/21477327/pubmed" id="21477327" target="_blank">21477327</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kauffman.1">
<a name="Kauffman.1"></a>Kauffman CA. Diagnosis and treatment of disseminated histoplasmosis in HIV-uninfected patients. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 4, 2022a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kauffman.2">
<a name="Kauffman.2"></a>Kauffman CA. Esophageal candidiasis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 25, 2021b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kauffman.3">
<a name="Kauffman.3"></a>Kauffman CA. Treatment of chronic pulmonary aspergillosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 28, 2020c.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kauffman.4">
<a name="Kauffman.4"></a>Kauffman CA. Treatment of sporotrichosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 27, 2022d.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17968818">
<a name="17968818"></a>Kauffman CA, Bustamante B, Chapman SW, Pappas PG; Infectious Diseases Society of America (IDSA). Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America. <i>Clin Infect Dis.</i> 2007;45(10):1255-1265.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/17968818/pubmed" id="17968818" target="_blank">17968818</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9418771">
<a name="9418771"></a>Kramer KE, Yaar M, Andersen W. Purpuric drug eruption secondary to itraconazole. <i>J Am Acad Dermatol</i>. 1997;37(6):994-995. doi:10.1016/s0190-9622(97)70080-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/9418771/pubmed" id="9418771" target="_blank">9418771</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21158923">
<a name="21158923"></a>Kramer MR, Amital A, Fuks L, Shitrit D. Voriconazole and itraconazole in lung transplant recipients receiving tacrolimus (FK 506): efficacy and drug interaction. <i>Clin Transplant</i>. 2011;25(2):E163-E167. doi:10.1111/j.1399-0012.2010.01373.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/21158923/pubmed" id="21158923" target="_blank">21158923</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28707751">
<a name="28707751"></a>Kreijkamp-Kaspers S, Hawke K, Guo L, et al. Oral antifungal medication for toenail onychomycosis. <i>Cochrane Database Syst Rev</i>. 2017;7(7):CD010031. doi:10.1002/14651858.CD010031.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/28707751/pubmed" id="28707751" target="_blank">28707751</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27927037">
<a name="27927037"></a>Kyriakidis I, Tragiannidis A, Munchen S, Groll AH. Clinical hepatotoxicity associated with antifungal agents. <i>Expert Opin Drug Saf</i>. 2017;16(2):149-165. doi:10.1080/14740338.2017.1270264<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/27927037/pubmed" id="27927037" target="_blank">27927037</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9669686">
<a name="9669686"></a>Lamy T, Bernard M, Courtois A, et al. Prophylactic use of itraconazole for the prevention of invasive pulmonary aspergillosis in high risk neutropenic patients. <i>Leuk Lymphoma</i>. 1998;30(1-2):163-174. doi:10.3109/10428199809050939<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/9669686/pubmed" id="9669686" target="_blank">9669686</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7979289">
<a name="7979289"></a>Law D, Moore CB, Denning DW. Bioassay for serum itraconazole concentrations using hydroxyitraconazole standards. <i>Antimicrob Agents Chemother</i>. 1994;38(7):1561-1566. doi:10.1128/AAC.38.7.1561<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/7979289/pubmed" id="7979289" target="_blank">7979289</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28614691">
<a name="28614691"></a>Le T, Kinh NV, Cuc NTK, et al; IVAP Investigators. A trial of itraconazole or amphotericin B for HIV-associated talaromycosis. <i>N Engl J Med</i>. 2017;376(24):2329-2340. doi:10.1056/NEJMoa1613306<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/28614691/pubmed" id="28614691" target="_blank">28614691</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29601447">
<a name="29601447"></a>Leong YH, Boast A, Cranswick N, Curtis N, Gwee A. Itraconazole dosing and drug monitoring at a tertiary children's hospital. <i>Pediatr Infect Dis J</i>. 2019;38(1):60-64. doi:10.1097/INF.0000000000002048<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/29601447/pubmed" id="29601447" target="_blank">29601447</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20185472">
<a name="20185472"></a>Lestner JM, Denning DW. Tremor: a newly described adverse event with long-term itraconazole therapy. <i>J Neurol Neurosurg Psychiatry</i>. 2010;81(3):327-329. doi:10.1136/jnnp.2009.174706<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/20185472/pubmed" id="20185472" target="_blank">20185472</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19681707">
<a name="19681707"></a>Lestner JM, Roberts SA, Moore CB, Howard SJ, Denning DW, Hope WW. Toxicodynamics of itraconazole: implications for therapeutic drug monitoring. <i>Clin Infect Dis</i>. 2009;49(6):928-930. doi:10.1086/605499<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/19681707/pubmed" id="19681707" target="_blank">19681707</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31691277">
<a name="31691277"></a>Liu D, Zhang C, Wu L, Zhang L, Zhang L. Fetal outcomes after maternal exposure to oral antifungal agents during pregnancy: a systematic review and meta-analysis. <i>Int J Gynaecol</i>
<i>Obstet</i>. 2020;148(1):6-13. doi:10.1002/ijgo.12993<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/31691277/pubmed" id="31691277" target="_blank">31691277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26597673">
<a name="26597673"></a>Lo Re V 3rd, Carbonari DM, Lewis JD, et al. Oral azole antifungal medications and risk of acute liver injury, overall and by chronic liver disease status. <i>Am J Med</i>. 2016;129(3):283-291.e5. doi:10.1016/j.amjmed.2015.10.029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/26597673/pubmed" id="26597673" target="_blank">26597673</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33904684">
<a name="33904684"></a>Makris M, Fokoloros C, Syrmali A, Tsakiraki Z, Damaskou V, Papadavid E. Generalized bullous fixed drug eruption to fluconazole with positive patch testing and confirmed tolerance to itraconazole. <i>Iran J Allergy Asthma Immunol</i>. 2021;20(2):255-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/33904684/pubmed" id="33904684" target="_blank">33904684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Marciano.1">
<a name="Marciano.1"></a>Marciano BE, Zerbe CS, Holland SM. Chronic granulomatous disease: treatment and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 18, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14616112">
<a name="14616112"></a>Martínez-Alonso JC, Domínguez-Ortega FJ, Fuentes-Gonzalo MJ. Urticaria and angioedema due to itraconazole. <i>Allergy</i>. 2003;58(12):1317-1318. doi:10.1046/j.0105-4538.2003.00316.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/14616112/pubmed" id="14616112" target="_blank">14616112</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21930637">
<a name="21930637"></a>Maxwell CB, Jenkins AT. Drug-induced heart failure. <i>Am J Health Syst Pharm</i>. 2011;68(19):1791-1804. doi:10.2146/ajhp100637<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/21930637/pubmed" id="21930637" target="_blank">21930637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32026639">
<a name="32026639"></a>Mayser P, Nenoff P, Reinel D, et al. S1 guidelines: tinea capitis. <i>J Dtsch Dermatol Ges</i>. 2020;18(2):161-179. doi:10.1111/ddg.14026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/32026639/pubmed" id="32026639" target="_blank">32026639</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10452633">
<a name="10452633"></a>McKinsey DS, Wheat LJ, Cloud GA, et al; National Institute of Allergy and Infectious Diseases Mycoses Study Group. Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: randomized, placebo-controlled, double-blind study. <i>Clin Infect Dis</i>. 1999;28(5):1049-1056. doi:10.1086/514744<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/10452633/pubmed" id="10452633" target="_blank">10452633</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30924967">
<a name="30924967"></a>Miller R, Assi M; AST Infectious Diseases Community of Practice. Endemic fungal infections in solid organ transplant recipients-guidelines from the American Society of Transplantation Infectious Diseases Community of Practice (AST-IDCOP). <i>Clin Transplant</i>. 2019;33(9):e13553. doi:10.1111/ctr.13553<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/30924967/pubmed" id="30924967" target="_blank">30924967</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15273137">
<a name="15273137"></a>Mohr JF, Finkel KW, Rex JH, Rodriguez JR, Leitz GJ, Ostrosky-Zeichner L. Pharmacokinetics of intravenous itraconazole in stable hemodialysis patients. <i>Antimicrob Agents Chemother.</i> 2004;48(8):3151-3153. doi:10.1128/AAC.48.8.3151-3153.2004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/15273137/pubmed" id="15273137" target="_blank">15273137</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.1">
<a name="NICE.1"></a>National Institute for Health and Care Excellence (NICE). Drug allergy: diagnosis and management. https://www.nice.org.uk/guidance/cg183. Published September 3, 2014. Accessed October 10, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nucci.2020">
<a name="Nucci.2020"></a>Nucci M, Colombo AL. Treatment of paracoccidioidomycosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 12, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26679628">
<a name="26679628"></a>Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2016;62(4):e1-e50. doi:10.1093/cid/civ933<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/26679628/pubmed" id="26679628" target="_blank">26679628</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9146550">
<a name="9146550"></a>Park YM, Kim JW, Kim CW. Acute generalized exanthematous pustulosis induced by itraconazole. <i>J Am Acad Dermatol</i>. 1997;36(5 Pt 1):794-796. doi:10.1016/s0190-9622(97)80353-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/9146550/pubmed" id="9146550" target="_blank">9146550</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9825096">
<a name="9825096"></a>Park H, Knowles S, Shear NH. Serum sickness-like reaction to itraconazole. <i>Ann Pharmacother</i>. 1998;32(11):1249. doi:10.1345/aph.17432<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/9825096/pubmed" id="9825096" target="_blank">9825096</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9784054">
<a name="9784054"></a>Parsad D, Saini R, Negi KS. Short-term treatment of pityrosporum folliculitis: a double blind placebo-controlled study. <i>J Eur Acad Dermatol Venereol</i>. 1998;11(2):188-190. doi:10.1111/j.1468-3083.1998.tb00781.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/9784054/pubmed" id="9784054" target="_blank">9784054</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Patterson.1">
<a name="Patterson.1"></a>Patterson TF. Treatment and prevention of invasive aspergillosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 5, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27365388">
<a name="27365388"></a>Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America (IDSA). <i>Clin Infect DisP</i>. 2016;63(4):e1-e60. doi:10.1093/cid/ciw326<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/27365388/pubmed" id="27365388" target="_blank">27365388</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28400399">
<a name="28400399"></a>Paul V, Rawal H. Cardiotoxicity with itraconazole. <i>BMJ Case Rep</i>. 2017;2017:bcr2017219376. doi:10.1136/bcr-2017-219376<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/28400399/pubmed" id="28400399" target="_blank">28400399</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20047480">
<a name="20047480"></a>Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2010;50(3):291-322.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/20047480/pubmed" id="20047480" target="_blank">20047480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26291595">
<a name="26291595"></a>Pettit NN, Pisano J, Weber S, Ridgway J. Hepatic failure in a patient receiving itraconazole for pulmonary histoplasmosis-case report and literature review. <i>Am J Ther</i>. 2016;23(5):e1215-e1221. doi:10.1097/MJT.0000000000000313<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/26291595/pubmed" id="26291595" target="_blank">26291595</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23416206">
<a name="23416206"></a>Qu Y, Fang M, Gao B, et al. Itraconazole decreases left ventricular contractility in isolated rabbit heart: mechanism of action. <i>Toxicol Appl Pharmacol</i>. 2013;268(2):113-122. doi:10.1016/j.taap.2013.01.029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/23416206/pubmed" id="23416206" target="_blank">23416206</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15792111">
<a name="15792111"></a>Roberts BJ, Friedlander SF. Tinea capitis: a treatment update. <i>Pediatr Ann</i>. 2005;34(3):191-200. doi:10.3928/0090-4481-20050301-08<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/15792111/pubmed" id="15792111" target="_blank">15792111</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29644223">
<a name="29644223"></a>Salem M, Reichlin T, Fasel D, Leuppi-Taegtmeyer A. Torsade de pointes and systemic azole antifungal agents: Analysis of global spontaneous safety reports. <i>Glob Cardiol Sci Pract</i>. 2017;2017(2):11. doi:10.21542/gcsp.2017.11<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/29644223/pubmed" id="29644223" target="_blank">29644223</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25614174">
<a name="25614174"></a>Salvator H, Mahlaoui N, Catherinot E, et al. Pulmonary manifestations in adult patients with chronic granulomatous disease. <i>Eur Respir J</i>. 2015;45(6):1613-1623. doi:10.1183/09031936.00118414<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/25614174/pubmed" id="25614174" target="_blank">25614174</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30829805">
<a name="30829805"></a>Schneller-Pavelescu L, Ochando-Ibernón G, Vergara-de Caso E, Silvestre-Salvador JF. Herpes simplex-like fixed drug eruption induced by fluconazole without cross-reactivity to itraconazole. <i>Dermatitis</i>. 2019;30(2):174-175. doi:10.1097/DER.0000000000000451<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/30829805/pubmed" id="30829805" target="_blank">30829805</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26339470">
<a name="26339470"></a>Schrijvers R, Gilissen L, Chiriac AM, Demoly P. Pathogenesis and diagnosis of delayed-type drug hypersensitivity reactions, from bedside to bench and back. <i>Clin Transl Allergy</i>. 2015;5:31. doi:10.1186/s13601-015-0073-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/26339470/pubmed" id="26339470" target="_blank">26339470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9919896">
<a name="9919896"></a>Schuller J, Remme JJ, Rampen FH, Van Neer FC. Itraconazole in the treatment of tinea pedis and tinea manuum: comparison of two treatment schedules. <i>Mycoses</i>. 1998;41(11-12):515-520. doi:10.1111/j.1439-0507.1998.tb00715.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/9919896/pubmed" id="9919896" target="_blank">9919896</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1648887">
<a name="1648887"></a>Sharkey PK, Rinaldi MG, Dunn JF, Hardin TC, Fetchick RJ, Graybill JR. High-dose itraconazole in the treatment of severe mycoses. <i>Antimicrob Agents Chemother</i>. 1991;35(4):707-713. doi:10.1128/AAC.35.4.707<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/1648887/pubmed" id="1648887" target="_blank">1648887</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28746570">
<a name="28746570"></a>Shikanai-Yasuda MA, Mendes RP, Colombo AL, et al. Brazilian guidelines for the clinical management of paracoccidioidomycosis. <i>Rev Soc Bras Med Trop</i>. 2017;50(5):715-740. doi:10.1590/0037-8682-0230-2017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/28746570/pubmed" id="28746570" target="_blank">28746570</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9597237">
<a name="9597237"></a>Sirisanthana T, Supparatpinyo K, Perriens J, Nelson KE. Amphotericin B and itraconazole for treatment of disseminated <i>Penicillium marneffei</i> infection in human immunodeficiency virus-infected patients. <i>Clin Infect Dis</i>. 1998;26(5):1107-1110. doi:10.1086/520280<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/9597237/pubmed" id="9597237" target="_blank">9597237</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20130764">
<a name="20130764"></a>Somchit N, Ngee CS, Yaakob A, Ahmad Z, Zakaria ZA. Effects of cytochrome p450 inhibitors on itraconazole and fluconazole induced cytotoxicity in hepatocytes. <i>J Toxicol</i>. 2009;2009:912320. doi:10.1155/2009/912320<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/20130764/pubmed" id="20130764" target="_blank">20130764</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30544724">
<a name="30544724"></a>Spernovasilis N, Kofteridis DP. Pre-existing liver disease and toxicity of antifungals. <i>J Fungi (Basel)</i>. 2018;4(4):133. doi:10.3390/jof4040133<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/30544724/pubmed" id="30544724" target="_blank">30544724</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sporanox.1">
<a name="Sporanox.1"></a>Sporanox (itraconazole) capsules [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; October 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sporanox.2">
<a name="Sporanox.2"></a>Sporanox (itraconazole) capsules [product monograph]. Toronto, Ontario, Canada: Janssen Inc; May 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sporanox.3">
<a name="Sporanox.3"></a>Sporanox (itraconazole) oral solution [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; October 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sporanox.4">
<a name="Sporanox.4"></a>Sporanox (itraconazole) oral solution [product monograph]. Toronto, Ontario, Canada: Janssen Inc; May 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15752292">
<a name="15752292"></a>Srebrnik A, Levtov S, Ben-Ami R, Brenner S. Liver failure and transplantation after itraconazole treatment for toenail onychomycosis. <i>J Eur Acad Dermatol Venereol</i>. 2005;19(2):205-207. doi:10.1111/j.1468-3083.2005.00943.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/15752292/pubmed" id="15752292" target="_blank">15752292</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12975753">
<a name="12975753"></a>Stevens DA, Moss RB, Kurup VP, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis--state of the art: Cystic Fibrosis Foundation Consensus Conference. <i>Clin Infect Dis</i>. 2003;37(suppl 3):S225-S264. doi:10.1086/376525<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/12975753/pubmed" id="12975753" target="_blank">12975753</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10717010">
<a name="10717010"></a>Stevens DA, Schwartz HJ, Lee JY, et al. A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. <i>N Engl J Med</i>. 2000;342(11):756-762. doi:10.1056/NEJM200003163421102<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/10717010/pubmed" id="10717010" target="_blank">10717010</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24595533">
<a name="24595533"></a>Stockmann C, Constance JE, Roberts JK, et al. Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications. <i>Clin Pharmacokinet</i>. 2014;53(5):429-454. doi:10.1007/s40262-014-0139-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/24595533/pubmed" id="24595533" target="_blank">24595533</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Supparatpinyo.1">
<a name="Supparatpinyo.1"></a>Supparatpinyo K. Diagnosis and treatment of Talaromyces (Penicillium) marneffei infection. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 25, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30179565">
<a name="30179565"></a>Taplitz RA, Kennedy EB, Bow EJ, et al. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update. <i>J Clin Oncol</i>. 2018;36(30):3043-3054. doi:10.1200/JCO.18.00374<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/30179565/pubmed" id="30179565" target="_blank">30179565</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33083707">
<a name="33083707"></a>Teaford HR, Abu Saleh OM, Villarraga HR, Enzler MJ, Rivera CG. The many faces of itraconazole cardiac toxicity. <i>Mayo Clin Proc Innov Qual Outcomes</i>. 2020;4(5):588-594. doi:10.1016/j.mayocpiqo.2020.05.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/33083707/pubmed" id="33083707" target="_blank">33083707</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34364529">
<a name="34364529"></a>Thompson GR 3rd, Le T, Chindamporn A, et al. Global guideline for the diagnosis and management of the endemic mycoses: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology (ECMM-ISHAM). <i>Lancet Infect Dis</i>. 2021;21(12):e364-e374. doi:10.1016/S1473-3099(21)00191-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/34364529/pubmed" id="34364529" target="_blank">34364529</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tolsura.1">
<a name="Tolsura.1"></a>Tolsura (itraconazole) [prescribing information]. Greenville, NC: Mayne Pharma; April 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19747629">
<a name="19747629"></a>Tomblyn M, Chiller T, Einsele H, et al; American Society of Blood and Marrow Transplantation. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. <i>Biol Blood Marrow Transplant</i>. 2009;15(10):1143-1238. doi:10.1016/j.bbmt.2009.06.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/19747629/pubmed" id="19747629" target="_blank">19747629</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35308776">
<a name="35308776"></a>Tsang D, Haddad S, Sternlieb M. Laryngeal blastomycosis with subsequent heart failure from itraconazole therapy. <i>IDCases</i>. 2022;28:e01463. doi:10.1016/j.idcr.2022.e01463<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/35308776/pubmed" id="35308776" target="_blank">35308776</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18523232">
<a name="18523232"></a>Tuccori M, Bresci F, Guidi B, Blandizzi C, Del Tacca M, Di Paolo M. Fatal hepatitis after long-term pulse itraconazole treatment for onychomycosis. <i>Ann Pharmacother</i>. 2008;42(7):1112-1127. doi:10.1345/aph.1L051<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/18523232/pubmed" id="18523232" target="_blank">18523232</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2174854">
<a name="2174854"></a>Tucker RM, Haq Y, Denning DW, Stevens DA. Adverse events associated with itraconazole in 189 patients on chronic therapy.<i> J Antimicrob Chemother</i>. 1990;26(4):561-566. doi:10.1093/jac/26.4.561<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/2174854/pubmed" id="2174854" target="_blank">2174854</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20000886">
<a name="20000886"></a>Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. <i>Clin Pharmacokinet.</i> 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/20000886/pubmed" id="20000886" target="_blank">20000886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2020">
<a name="HHS.2020"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-oi/guidelines-adult-adolescent-oi.pdf" target="_blank">https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-oi/guidelines-adult-adolescent-oi.pdf</a>. Updated May 26, 2020. Accessed August 18, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2022">
<a name="HHS.2022"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. <a href="https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/whats-new" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/whats-new</a>. Updated July 24, 2023. Accessed August 23, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Children with and Exposed to HIV. Guidelines for the prevention and treatment of opportunistic infections in children with and exposed to HIV. <a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/pediatric-oi/guidelines-pediatric-oi.pdf" target="_blank">https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/pediatric-oi/guidelines-pediatric-oi.pdf</a>. Updated August 3, 2023. Accessed August 23, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2019">
<a name="HHS.2019"></a>US Department of Health and Human Services (HHS) Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the use of antiretroviral drugs during pregnancy and interventions to reduce perinatal HIV transmission in the United States. <a href="https://clinicalinfo.hiv.gov/en/guidelines/perinatal/whats-new" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/perinatal/whats-new</a>. Updated December 24, 2019. Accessed January 2, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28017630">
<a name="28017630"></a>Vignesh P, Gupta A, Dogra S. Malar rash in a child with chronic granulomatous disease. <i>J Allergy Clin Immunol Pract</i>. 2017;5(2):473-474. doi:10.1016/j.jaip.2016.11.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/28017630/pubmed" id="28017630" target="_blank">28017630</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20308378">
<a name="20308378"></a>Wang JL, Chang CH, Young-Xu Y, Chan KA. Systematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection. <i>Antimicrob Agents Chemother</i>. 2010;54(6):2409-2419. doi:10.1128/AAC.01657-09<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/20308378/pubmed" id="20308378" target="_blank">20308378</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12743557">
<a name="12743557"></a>Wark PA, Hensley MJ, Saltos N, et al. Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: a randomized controlled trial. <i>J Allergy Clin Immunol</i>. 2003;111(5):952-957. doi:10.1067/mai.2003.1388<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/12743557/pubmed" id="12743557" target="_blank">12743557</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17806045">
<a name="17806045"></a>Wheat J, Freifeld AG, Kleiman MB, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. <i>Clin Infect Dis.</i> 2007;45(7):807-825. doi:10.1086/521259<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/17806045/pubmed" id="17806045" target="_blank">17806045</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wingard.1">
<a name="Wingard.1"></a>Wingard JR. Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 10, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17555487">
<a name="17555487"></a>Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/17555487/pubmed" id="17555487" target="_blank">17555487</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30197526">
<a name="30197526"></a>Zhang J, Liu Y, Nie X, Yu Y, Gu J, Zhao L. Trough concentration of itraconazole and its relationship with efficacy and safety: a systematic review and meta-analysis. <i>Infect Drug Resist</i>. 2018;11:1283-1297. doi:10.2147/IDR.S170706<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/30197526/pubmed" id="30197526" target="_blank">30197526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29893422">
<a name="29893422"></a>Zhang L, Xu H, Shi Y, Yu J, Tao Y, Li X. An exploration of the optimum dosage and number of cycles of itraconazole pulse therapy for severe onychomycosis. <i>Mycoses</i>. 2018;61(10):736-742. doi:10.1111/myc.12799<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/itraconazole-pediatric-drug-information/abstract-text/29893422/pubmed" id="29893422" target="_blank">29893422</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13396 Version 491.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
